

MAX FINK, M.D.

11 Buttonfield Lane
South Hadley, MA 01075 Cell: 631.637.1730

fink.max@gmail.com
maxfink55@gmail.com

PRESENT APPOINTMENT

Professor of Psychiatry and Neurology, Stony Brook University 1972-1997
Professor Emeritus 1997-

CERTIFICATIONS

Diplomate, National Board of Medical Examiners 1946

Diplomate, American Board of Psychiatry and Neurology
Certified in Neurology 1952
Certified in Psychiatry 1954

William Alanson White Institute of Psychoanalysis 1953
Certificate in Psychoanalysis for Physicians

License, Practice of Medicine and Surgery
New York 1946
Missouri 1962

EDUCATION

University College, University Heights Campus 1939-1942
New York University, B.A. cum laude, Honors in Biology

New York University College of Medicine, M.D. 1942-1945

William Alan White Institute for Psychoanalysis 1948-1953
Certificate in psychoanalysis for physicians

Morrisania City Hospital, Rotating Internship July 1945-April 1946

Montefiore Hospital, Residency in Neuropsychiatry July 1948-June 1949

Bellevue Psychiatric Hospital, Residencies in Neurology and Psychiatry July 1949-December 1951

Hillside Hospital, Resident in Psychiatry January 1952-December 1952

Mount Sinai and Hillside Hospitals, Fellow in Neuropsychiatry; National Foundation for Infantile Paralysis (also January 1951-December 1951) January 1953-December 1953

ACADEMIC and RESEARCH AWARDS

C. Charles Burlingame Award, Lecture, Institute for Living, CT	2019
Thomas William Salmon Award and Medal, New York Academy of Medicine	2011
Honorary Member, Associazione Italiana per la Terapia Elettroconvulsivante (AITEC)	2006
Honorary Member, European Forum for Electroconvulsive Therapy (EFFECT)	2006
Honorary Fellow, International Pharmacology-EEG Society (IPEG)	2000
Fellow, Association for Convulsive Therapy	2000
Arrigo Prize for Lifetime Achievement in Neurophysiology, University of Pavia	1998
Lifetime Achievement Award, Society of Biological Psychiatry	1996
Lifetime Achievement Award, <i>Psychiatric Times</i> and CME, Inc.	1995
Gold Medal Award of the Society of Biological Psychiatry	1988
Laszlo Meduna Prize of the Hungarian National Institute for Nervous and Mental Diseases	1986
Taylor Manor Hospital Psychiatric Award	1983
Anna Moniker Foundation Prize for Contributions to the Study of Endogenous Depression	1979
Samuel W. Hamilton Award, American Psychopathological Association	1974
Alpha Omega Alpha, New York University	1973
A.E. Bennett Psychiatric Research Award, Society of Biological Psychiatry	1958
Electroshock Research Association Award	1956
Elected Phi Beta Kappa and Alpha Pi Christopher Coates Biology Prize Phi Lambda Upsilon Chemistry Prize, New York University	1939-1942

TEACHING AWARDS

“Teacher of the Year,” Department of Psychiatry
Stony Brook University 1992, 1993, 1996

MEMBERSHIPS

Distinguished Life Fellow

American Psychiatric Association (APA)
Secretary, Chairman, section on Brain Function and Behavior 1957, 1958, 1962
Member, Task Force on Electroconvulsive Therapy 1975-1978, 1988-1990
Nassau Neuropsychiatric Society 1954-1962 (President, 1959)
Suffolk County District Branch 1973-

Fellow

New York Academy of Medicine

American College of Neuropsychopharmacology (ACNP)

Association for Convulsive Therapy

International -Pharmaco-EEG (IPEG)

Vice President 1981-1984
Councillor 1986-1990
Honorary Fellow 2000

Senior Member

Society of Biological Psychiatry 1960

Member

American Psychopathological Association
Secretary 1968-1971
Vice President 1971-1972
President-Elect 1972-1973
President 1973-1974

Association for Convulsive Therapy

Chairman, Task Force on Ambulatory ECT 1995

Collegium Internationale Neuro-Psychopharmacologicum
(CINP) 1960

Deutsche EEG Gesellschaft 1962

International Brain Research Organization (IBRO) 1964

International Society for Psychoneuroendocrinology 1964

Instituto de Psiquatria y Psicologia de Montevideo 1964

World Federation of Societies of Biological Psychiatry
Chairman, Task Force on ECT 2002-2005

EDITORIAL APPOINTMENTS

Founding Editor, *Convulsive Therapy*, 1984-1994
Editorial Board, 1995-

Contributing Editor

Comprehensive Psychiatry (1972-2000)
Currents Developments in Psychopharmacology
Directions in Psychopharmacology
Journal of Clinical Psychiatry (1980-1999)
Neuropsychiatry, Neuropsychology & Behavioral Neurology (1988-2003)
Neuropsychology (Associate Editor, Pharmacology-EEG, 1983-1997)
Pharmacopsychiatry
Psychiatric Journal, University of Ottawa (1980-1992)
Clinical Pharmacology & Therapeutics (1977-1981)
Psychopharmacologia (1975-1978)
Sleep & Wakefulness (1978-1981)

PRIOR APPOINTMENTS

Academic

Assistant in Neurology, New York University	1952-1954
Research Professor of Psychiatry, Washington University	1962-1966
Professor of Psychiatry, University of Missouri	1963-1966
Visiting Professor	
University of Istanbul	1968, 1969
National Institute of Neurology of Mexico	1969
University of California at Irvine	1976
Organon Special Visiting Lectureship, Netherlands	1988
Honorary Member, Societe Royale de Medecine Mentale de Belgique	1969
Professor of Psychiatry, Albert Einstein College of Medicine	1998-2005

Hospital

Staff Neurologist, Long Island Jewish Hospital	1954-1959
Associate Attending Neurologist, North Shore Hospital	1954-1962
Supervising Psychiatrist; Director of Research Director, Department of Experimental Psychiatry Hillside Hospital, Glen Oaks, NY	1954-1962
Director, Missouri Institute of Psychiatry, St. Louis, MO	1962-1966
Director, Division of Biological Psychiatry, NY Medical College	1966-1973
Attending Psychiatrist Metropolitan Medical Center	1965-1973
Flower & Fifth Avenue Hospitals	1966-1973
Bird S. Coler Hospital	1966-1973
University Hospital, Stony Brook University	1980-1997
Consulting Psychiatrist Grasslands Hospital	1971-1973
Central Islip Psychiatric Center	1974-1979
V.A. Hospital, Northport, NY	1972-1981
Director, Division of Clinical Sciences Long Island Research Institute	1976-1983
Attending Psychiatrist, Department of Psychiatry Long Island Jewish Hillside Hospital	1981-2005

CONSULTANT

Committee on Clinical Drug Evaluation Psychopharmacology Service Center, NIMH	1962-1965
Division of Mental Diseases of the State of Missouri	1962-1966
VA-NIMH-SAODAP Collaborative Studies in Opiate Dependence	1972-1974
Bureau of Drugs, Food & Drug Administration	1970-1973
American Psychiatric Association Task Force on ECT	1975-1978
V.A. Merit Review Board on Behavioral Sciences	1977-1980
German BGA Commission of Pharmacology-EEG	1980-1981
NIMH Committee on Collaborative ECT Project	1980-1982

National Academy of Sciences, National Research Council
Committee on Toxicology: Committee on Anticholinergic
Drugs Panel 1981-1982

U.S. Army Workshop on the Feasibility of Using
Incapacitating Agents Against Terrorists 1986

American Psychiatric Association Task Force on
Electroconvulsive Therapy 1988-1990

MILITARY SERVICE

Captain, U.S. Army Medical Corps. 1946-1947
School of Military Neuropsychiatry, Fort Sam Houston
Chief, NP Clinical Service, Fort Knox Station Hospital

PRIVATE PRACTICE

Ship Surgeon
Grace Line 1947-1948
American Export Line 1948

Neurology and Psychiatry 1954-1958
275 Middle Neck Road, Great Neck, NY

PUBLICATIONS

1950

1. Subdural hematoma developing during hospitalization. *Amer. J. Psychiat.*, 107: 381-383 (with M. Green).
- 2a. Patterns in perception of simultaneous tests of face and hand. *Trans. Amer. Neurol. Ass.*, 75: 250 (with M.B. Bender and M. Green). (abstract).

1951

- 2b. ...ibid., *Arch. Neurol. Psychiat. (Chic.)*, 66: 355-362.

1952

3. The face-hand test as a diagnostic sign of organic mental syndrome. *Neurology (Minneap.)*, 2: 46-58 (with M.B. Bender and M. Green).
4. Tactile perceptual tests in the differential diagnosis of psychiatric disorders. *J. Hillside Hosp.*, 1: 21-31 (with M.B. Bender).
5. A clinical evaluation of carotid angiography. *Contin Neurol. (Basel)*, 12: 181-195 (with J.M. Stein).
- 6a. Exosomesthesia, or displacement of cutaneous sensation into extra-personal space. *Trans. Amer. Neurol. Ass.*, 77: 260-262 (with M.F. Shapiro and M.B. Bender). (abstract).
- 6b. ...ibid., *Arch. Neurol. Psychiat. (Chic.)*, 68: 481-490.
- 7a. Order of dominance in cutaneous perception. *Trans. Amer. Neurol. Ass.*, 77: 238-240 (with M.B. Bender and M. Green). (abstract).
- 7b. Patterns of perceptual organization with simultaneous stimuli. *Arch. Neurol. Psychiat. (Chic.)*, 72: 233-255 (with M.B. Bender and M. Green), 1954.

1953

8. Perception of simultaneous tactile stimuli in normal children. *Neurology (Minneap.)*, 3: 27-34 (with M. B. Bender).
9. Perception of simultaneous tactile stimuli by mentally defective subjects. *J. Nerv. Ment. Dis.*, 117: 43-49 (with M.B. Bender and M. Green).
10. Spinal fluid findings following cerebral angiography. *Neurology (Minneap.)*, 3: 137 (with J.M. Stein).
11. A statistical study of a psychoanalytic hypothesis: absence of a parent as a specific factor determining choice of neurosis. *J. Hillside Hosp.*, 2: 67-71 (with S. Tarachow).

12. Effects of intravenous barbiturate on perception. *Trans. Amer. Neurol. Ass.*, 78: 244-245 (with M.B. Bender, P. Bergman, and M. Nathanson). (abstract).

13. Homosexuality with panic and paranoid states case report. *J. Hillside Hosp.*, 2: 164-190.

1954

14. Standardization of the face-hand test. *Neurology (Minneap.)*, 4: 211-217 (with M. Green).

1955

15. The "Amytal test" in patients with mental illness. *J. Hillside Hosp.*, 4: 3-13 (with R.L. Kahn and E.A. Weinstein).

16. Delusional reduplication of parts of body after insulin coma therapy. *J. Hillside Hosp.*, 4: 134-147 (with R.L. Kahn and D. Graubert).

1956

17. Relation of Amobarbital test to clinical improvement in electroshock. *Arch. Neurol. Psychiat. (Chic.)*, 76: 23-29 (with R.L. Kahn and E.A. Weinstein).

18. Evaluation of high dose reserpine therapy for the relief of anxiety. *J. Hillside Hosp.*, 5: 67-77 (with M. Wachspress, A.G. Blumberg, and J.S.A. Miller).

19. Relation of Changes in Memory and Learning to Improvement in Electroshock. *Confin. Neurol. (Basel)*, 16: 88-96 (with H. Korin and S. Kwalwasser).

20. Denial of blindness following cerebral angiography. *J. Hillside Hosp.*, 5: 238-245.

21a. Quantitative studies of slow wave activity following electroshock. *Electroenceph. Clin. Neurophysiol.*, 8: 158 with R.L. Kahn). (abstract).

21b. Relation of EEG delta activity to behavioral response in electroshock: quantitative serial studies. *Arch. Neurol. Psychiat. (Chic.)*, 78: 516-525, 1957 (with R.L. Kahn).

1957

22a. EEG and clinical response to Megimide. *Electroenceph. Clin. Neurophysiol.*, 9: 180 (with M. Green). (abstract).

22b. Clinical and electroencephalographic effects of Megimide in patients without cerebral disease. *Neurology (Minneap)*, 8: 682-685 (with M. Green).

23. A unified theory of the action of physiodynamic therapies. *J. Hillside Hosp.*, 6: 197-206.

24. Perception of embedded figures after induced altered brain function. *American Psychologist*, 12: 361 (with R.L. Kahn).

25. Social factors in selection of therapy in a voluntary mental hospital. *J. Hillside Hosp.*, 6: 216-228 (with R.L. Kahn and M. Pollack).

26. Role of stimulus intensity in perception of simultaneous cutaneous electrical stimuli. *J. Hillside Hosp.*, 6: 241-250 (with H. Korin).

Added 2/25/17 Soviet Medical Advances: Importance of making literature available to American scientists. New York Times Letters, 15 Nov 1957, pg 26.

1958

27. Changes in language during electroshock therapy. In P.H. Hoch and J. Zubin (eds.), *Psychopathology of Communication*. Grune and Stratton, New York, 1958: 126-139 (with R.L. Kahn).

28. Lateral gaze nystagmus as an index of the sedation threshold. *Electroenceph. Clin. Neurophysiol.*, 10: 162-163.

29a. Effects of Diethazine on EEG and significance for theory of convulsive therapy. *Electroenceph. Clin. Neurophysiol.* 10: 207-208. (abstract).

29b. Effect of anticholinergic agent, Diethazine, on EEG and behavior: significance for theory of convulsive therapy. *Arch. Neurol. Psychiat. (Chic.)*, 80: 380-387.

29c. ...ibid., In J.H. Masserman (ed.), *Biological Psychiatry*. Grune and Stratton, New York, 1959, 1: 184-194.

30. Experimental studies of the electroshock process. *Dis. Nerv. Syst.*, 19: 113-118 (with R.L. Kahn and M. Green).

31. Comparative study of Chlorpromazine and insulin coma in the therapy of psychosis. *J. Amer. Med. Ass.*, 166: 1846-1850 (with R. Shaw, G. Gross, and F.S. Coleman).

32. Electroencephalographic correlates of the electroshock process. *Dis. Nerv. Syst.*, 19: 227 (with M. Green). (abstract).

33a. Experimental studies of convulsive and drug therapies in psychiatry: theoretical implications. *Arch. Neurol. Psychiat. (Chic.)*, 80: 733-734 (with R.L. Kahn and M.A. Green). (abstract).

33b. Alteration of brain function in therapy. In N.S. Kline (ed.), *Psychopharmacology Frontiers*. Little, Brown & Co., Boston, 1959: 325-332.

34a. Effect of anticholinergic compounds on post-convulsive electroencephalogram and behavior. *Electroenceph. Clin. Neurophysiol.*, 10: 776. (abstract).

34b. Effect of anticholinergic compounds on post-convulsive electroencephalogram and behavior of psychiatric patients. *Electroenceph. Clin. Neurophysiol.*, 1960, 12: 359-369.

1959

35. Effects of diffuse altered brain function on perception. In *Proc. XV Int. Congr. Psychol.* North Holland, Amsterdam: 238-239 (with R.L. Kahn and H. Korin). (abstract).

36. Psychological factors affecting individual differences in behavioral response to convulsive therapy. *J. Nerv. Ment. Dis.*, 128: 243-248 (with R.L. Kahn and M. Pollack).

37a. Significance of EEG pattern changes in psychopharmacology. *Electroenceph. Clin. Neurophysiol.*, 11: 398. (abstract) .

37b. EEG and behavioral effects of psychopharmacologic agents. In P. B. Bradley, P. Deniker, and C. Radouco-Thomas (eds.), *Neuro-Psychopharmacology*. Elsevier, Amsterdam, 1959, 1: 441-446.

38a. Electroencephalographic and behavioral effects of Tofranil. *Canad. Psychiat. Assoc. J.*, 4 *Suppl.*: 166-171.

38b. ...*ibid.*, *Electroenceph. Clin. Neurophysiol.*, 1960, 12: 243-244. (abstract).

39. Relation of tests of altered brain function to behavioral change following induced convulsions. In L. van Bogaert and J. Radermecker (eds.), *First International Congress of Neurological Sciences*. Pergamon Press, London, 1959, 3: 613-619 (with R.L. Kahn and H. Korin).

40. The Role of set in the perception of simultaneous tactile stimuli. *Amer. J. Psychol.*, 72: 384-392 (with H. Korin).

41. Personality factors in behavioral responses to electroshock therapy. *J. Neuropsychiat.*, 1: 45-49 (with R.L. Kahn).

42. Sociopsychologic aspects of psychiatric treatment in a voluntary mental hospital: duration of hospitalization, discharge ratings and diagnosis. *Arch. Gen. Psychiat.*, 1: 565-574 (with R.L. Kahn and M. Pollack).

1960

43. Efficacy of divided and single dose schedules in insulin coma therapy. *Amer. J. Psychiat.*, 116: 839-840 (with A.G. Blumberg and P. Laderman).

44. Changes in verbal transactions with induced altered brain function. *J. Nerv. Ment. Dis.*, 130: 235-239 (with J. Jaffe and R.L. Kahn).

45. Drug induced changes in interview patterns: linguistic and neurophysiologic indices. In G.J. Sarwer-Foner (ed.), *The Dynamics of Psychiatric Drug Therapy*. C.C. Thomas, Springfield, IL, 1960: 29-44 (with J. Jaffe and R.L. Kahn).

46. Social attitude California F Scale and convulsive therapy. *J. Nerv. Ment. Dis.*, 130: 187-192 (with R.L. Kahn and M. Pollack).

47. Figure-ground discrimination after induced altered brain function. *Arch. Neurol. (Chic.)*, 2: 547-551 (with R.L. Kahn and M. Pollack).

48. Prognostic value of Rorschach criteria in clinical response to convulsive therapy. *J. Neuropsychiat.*, 1: 242-245 (with R.L. Kahn).

1961

49. Modification of psychotherapeutic transactions by altered brain function. *Amer. J. Psychother.*, 15: 46-55 (with J. Jaffe, H. Esecover, R.L. Kahn).

50. Neuropsychologic response patterns of some psychotropic drugs. In E. Rothlin (ed.), *Neuropsychopharmacology*. Elsevier, Amsterdam, 1961, 2: 381-384 (with M. Pollack, E. Karp, G. Krauthamer, and D.F. Klein).
51. ...*ibid.*, Problems of antagonists to psychotropic drugs, 30-32.
52. Inhalant-induced convulsions. *Arch. Gen. Psychiat.*, 4: 259-266 (with R.L. Kahn, E. Karp, M. Pollack, M.A. Green, B. Alan, H.J. Lefkowitz).
53. Behavioral patterns in convulsive therapy. *Arch. Gen. Psychiat.*, 5: 30-36 (with R.L. Kahn).
54. Sociopsychological characteristics of patients who refuse convulsive therapy. *J. Nerv. Ment. Dis.*, 132: 153-157 (with M. Pollack).
55. EEG techniques in study of psychotropic drugs. *Acta of the International Meeting on the Techniques for the Study of Psychotropic Drugs*, Bologna, 1960. Societa Tipografica Modenese, Modena, 1961: 3pp.
56. Withdrawal symptoms following discontinuation of Imipramine therapy. *Amer. J. Psychiat.*, 118: 549-550 (with J.C. Kramer and D.F. Klein).
57. Experimental psychiatric research at Hillside: review and prospect. *J. Hillside Hosp.*, 10: 159-169.
58. Prediction of individual patient response to convulsive therapy. *VA Cooperative Chemotherapy Studies in Psychiatry*, 6: 317-324.
59. Social aspects of psychiatric treatment in three hospitals: methodological problems. *VA Cooperative Studies in Psychiatry*, 6: 202-206 (with M. Pollack, N. Siegel, and R.L. Kahn).
- 59b. Sociopsychological aspects of psychiatric treatment in three voluntary hospitals. *A.M.A. Arch. Gen. Psychiat.*, 14: 20-25 (with R.L. Kahn and N. Siegel).
60. Quantitative electroencephalography and human psychopharmacology: I. Frequency spectra and drug action. *Med. Exp. (Basel)*, 5: 364-369.
- 1962**
61. The critical flicker frequency and EEG alpha: a reliability study. *Electroenceph. Clin. Neurophysiol.*, 14: 60-63 (with E. Karp and M. Pollack).
62. The mode of action of convulsive therapy: the neurophysiologic-adaptive view. *J. Neuropsychiat.*, 3: 231-233.
63. Disordered perception of simultaneous stimulation of face and hand: a review and theory. In J. Wortis (ed.), *Biological Psychiatry*. Plenum Press, Inc., New York, 1962, 4: 362-369 (with M. Pollack).
64. Tachistoscopic perception after induced altered brain function: influence of mental set. *J. Nerv. Ment. Dis.*, 134: 422-430 (with M. Pollack, R.L. Kahn, and E. Karp).
65. Motivation for psychotherapy. *Comprehens. Psychiat.*, 3: 170-173 (with N. Siegel).
66. Psychiatric reaction patterns to Imipramine (Tofranil). *Amer. J. Psychiat.*, 119: 432-438

(with D.F. Klein).

67. Behavioral reaction patterns with Phenothiazines. *Arch. Gen. Psychiat.*, 7: 449-459 (with D.F. Klein).

68. The disposition of applications for psychotherapy in an out-patient clinic. *Social-Casework*, 43: 545-547 (with N. Siegel).

69. Social class, diagnosis, and treatment in three psychiatric hospitals. *Social-Problems*, 10: 191-196 (with N. Siegel, R.L. Kahn, and M. Pollack).

70. Imipramine as an adjunct to Phenothiazine therapy. *Comprehens. Psychiat.*, 3: 377-380 (with J.C. Kramer and D.F. Klein).

1963

71. EEG and human psychopharmacology. Abstracts of Proceedings of Symposium at Third World Congress of Psychiatry, Montreal, 1961). *Electroenceph. Clin. Neurophysiol.*, 15: 133-137.

72. Multiple item factors as change measures in psychopharmacology. *Psychopharmacologia (Berl.)*, 4: 43-52 (with D.F. Klein).

73. Quantitative electroencephalography in human psychopharmacology II: drug patterns. In G. Glaser (ed.), *EEG and Behavior*. Basic Books, Inc., New York, 177-197.

74. Effects of Imipramine and Chlorpromazine on perceptual analytic ability, perceptual responsivity and memory as revealed in Rorschach responses. *J. Nerv. Ment. Dis.*, 137: 42-50 (with I. Belmont, M. Pollack, and A. Willner).

1964

75. A selected bibliography of electroencephalography in human psychopharmacology, 1951-1962. *Electroenceph. Clin. Neurophysiol., Suppl.* 23, 68 pp.

76. Comparative study of period analysis and frequency analysis of the electroencephalogram. *Electroenceph. Clin. Neurophysiol.*, 17: 454-455. (with N. Burch). (abstract).

77. Comparative studies of Chlorpromazine and Imipramine I: drug discrimination patterns. In P.B. Bradley, F. Flugel, and P.H. Hoch (eds.), *Neuro-Psychopharmacology*. Elsevier, Amsterdam, 3: 370-372 (with M. Pollack, D.F. Klein, A.G. Blumberg, I. Belmont, E. Karp, J.C. Kramer, and A. Willner).

78. Comparative studies of Chlorpromazine and Imipramine II: psychological performance profiles. In P.B. Bradley, F. Flugel, and P.H. Hoch (eds.), *Neuro-Psychopharmacology*. Elsevier, Amsterdam, 3: 373-376 (with M. Pollack, E. Karp, I. Belmont and A. Willner).

79. Digital computer analysis of EEG using an IBM 1710 system. *Electroenceph. Clin. Neurophysiol.*, 17: 712 (with D. Shapiro, D. Bridger and T. Itil). (abstract).

1965

80. Clinical efficacy of Chlorpromazine-Procyclidine combination, Imipramine and placebo in depressive disorders. *Psychopharmacologia (Berl.)*, 7: 27-36 (with D.F. Klein and J. Kramer).

81. Imipramine-induced behavioral disorganization in schizophrenic patients: physiological and psychological correlates. In J. Wortis (ed.), *Biological Psychiatry*. Plenum Press, Inc., New York, 7: 53-61 (with M. Pollack, D.F. Klein, A. Willner, and A.G. Blumberg).

82a. EEG analyses by digital computer, I: development of IBM 1710 System. *Electroenceph. Clin. Neurophysiol.*, 18: 520 (with T. Itil, D. Shapiro, and D. Bridger). (abstract).

82b. EEG analyses by digital computer, II: relation of pentothal induced changes to resting pattern. *Electroenceph. Clin. Neurophysiol.*, 18: 520-21 (with T. Itil). (abstract).

83. Quantitative EEG and human psychopharmacology, III: changes on acute and chronic administration of Chlorpromazine, Imipramine and placebo saline. In W. P. Wilson: *Applications of Electroencephalography in Psychiatry*. Duke University Press, Durham, North Carolina, 226-240.

84. Clinical neurophysiology. In D. Bente and P. Bradley (eds.), *Neuro-Psychopharmacology*, Elsevier, Amsterdam, 4: 64-69.

1966

85. Klinische Untersuchungen und quantitative EEG-daten bei experimentellen Psychosen. *Arzneimittel-Forsch.*, 16: 237-240 (with T. Itil).

86. Die Anwendung von Digital-Computer Methoden in der Psychopharmakologie. *Arzneimittel-Forsch.*, 16: 297-299 (with T. Itil and D. Shapiro).

87. Trifluoperidol in the treatment of psychosis. observations suggestive of anticholinergic activity at higher dosages. *J. New Drugs*, 6: 174-181 (with A. Don, M. Stallings, T. Itil and J.M. Holden).

88. Cholinergic mechanisms in mental illness: anticholinergic hallucinogens. In J. Wortis (ed.), *Recent Advances in Biological Psychiatry*, Plenum Press, Inc., N.Y., 8: 115-119.

89. ...ibid., Drug induced or spontaneous psychopathological changes and the relationship to quantitative electroencephalography, 8: 303 (with T. Itil and A. Keskiner). (abstract).

90. ...ibid., Classification of psychosis by quantitative EEG measures, 8: 305-312 (with T. Itil and D. Clyde).

91. Cholinergic aspects of convulsive therapy. *J. Nerv. Ment. Dis.*, 142: 475-484.

92. The question of dissociation of EEG and behavior with anticholinergic agents. *Electroenceph. Clin. Neurophysiol.*, 21: 41 (with T. Itil). (abstract).

93. Prolonged adverse reactions to LSD in psychotic subjects. *Arch. Gen. Psychiat.*, 142: 450-454 (with J. Simeon, W. Haque, and T. Itil)

94. Behavior and quantitative EEG changes induced by hallucinogenic drugs. *Proc. XVIII Int. Cong. Psychol., (Moscow) I*: 224 (with T. Itil). (abstract).

95. Anticholinergic drug induced delirium experimental modification, quantitative EEG and behavioral correlations. *J. Nerv. Ment. Dis.*, 143: 492-507 (with T. Itil).

96. Therapeutic studies in therapy resistant schizophrenic patients. *Comprehens. Psychiat.*, 7: 488-493

(with T. Itil and A. Keskiner).

1967

97. Clinical trial of Navane Thiothixene in schizophrenia. *Curr. Ther. Res.*, 9: 10-16. (with J. Simeon, A. Keskiner, D. Ponce, T. Itil).
98. Clinical laboratory test standards in new drug trials. *J. Clin. Pharmacol. and New Drugs*, 7: 1-8. (with J. M. Holden, T. Itil, J. Simeon).
99. Organic treatment of schizophrenia. In *Textbook of Psychiatry*, A.M. Freedman and H. Kaplan (eds.). Williams and Wilkins, Baltimore, pp. 661-664 (with T. Itil).
- 100a. ...ibid., *Computers and psychiatry*, Chapter 5.2, pp. 232-238.
- 100b. ...ibid., *Human Behavior: Biological, Psychological, and Sociological*, A.M. Freedman and H. Kaplan (eds.), Atheneum, 1972, 450-460.
- 101a. Quantitative analysis of the electroencephalogram by digital computer methods. III. Applications to psychopharmacology. *VII IBM Medical Symposium*, Poughkeepsie, IBM Press, pp. 263-290.
- 101b . . .ibid., *Computers and Electronic Devices in Psychiatry*, N.S. Kline and E. Laska (eds.), Grune and Stratton, 109-123, 1968 (with D.M. Shapiro, C. Hickman and T. Itil).
102. Through a mirror darkly. Review of *Psychopathology of Perception*. P.H. Hoch and J. Zubin (eds.), N.Y., Grune and Stratton. *Contemp. Psychol.*, 11: 536-538.
103. Altered sensitivity to centrally active drugs following lobotomy. In J. Wortis (ed.), *Biological Psychiatry*, Plenum Press, Inc. N.Y., 9: 157-170 (with T. Itil, J. Holden, A. Keskiner).
104. Effect of Sulthiame in schizophrenic patients. *Proc. First Int. Cong. Acad. Psychosom. Med.*, E. Dunlop (ed.) pp. 185-194, Amsterdam, Excerpta Med. Fdn. (with T. Itil, A. Keskiner).
105. Digital computer analysis of the human EEG in psychiatric research. *Comprehens. Psychiat.*, 8: 521-538 (with T. Itil and D. Shapiro).
- 106a. EEG and behavioral aspects of the interaction of anticholinergic hallucinogens with centrally active compounds. *Anticholinergic Drugs and Brain Functions in Animals and Man*, P. Bradley and M. Fink (eds.), Elsevier, Amsterdam, pp. 149-168 (with T. Itil).
- 106b. Anticholinergic hallucinogens and their interaction with centrally active drugs. *Neuropsychopharmacology*, H.Brill (ed.), *Excerpta Medica*, Amsterdam, pp. 381 (with T. Itil).
107. Anticholinergic drugs and brain function in animals and man. *Neuro-psychopharmacology*, H. Brill (ed.), *Excerpta Medica*, Elsevier, Amsterdam, pp. 374-390.
108. Treatment of chronic psychotic patients with combined medications. *Neuropsychopharmacology*, H. Brill (ed.), *Excerpta Medica*, Amsterdam, pp. 1016-1020 (with T. Itil, J. Holden, D. Shapiro, A. Keskiner).
109. EEG Patterns with combined drug treatments in psychotic patients. *Turk J. Electroenceph. Clin. Neurophysiol.*, 1: 1-9 (with T. Itil, G. Ulett).

110. *Anticholinergic Drugs and Brain Functions in Animals and Man*, P. Bradley and M. Fink (eds.), *Progress in Brain Research*, Vol. 28, Elsevier, Amsterdam, pp. 375, 1968.
111. Brain, behavior and anticholinergic drugs. *Anticholinergic Drugs, and Brain Functions in Animals and Man*, P. Bradley and M. Fink (eds.), Elsevier, Amsterdam, pp. xii-xvi.
112. Quantitative EEG: A new dimension in psychopharmacology. *Proceedings IV World Congress Psychiat., Excerpta Med. Fdn.*, Amsterdam, pp. 338-339.
- 113a. The differentiation of tranquilizers by quantitative EEG. *Electroenceph. Clin. Neurophysiol.* 24 (with T. Itil, D. Shapiro, C. Hickman, and N. Kiremitci). (abstract).
- 113b. Quantitative EEG Studies of Chlordiazepoxide, Chlorpromazine and Imipramine in volunteer and schizophrenic subjects. *Psychopharmacology of the Normal Human*, W. Evans and N.S. Kline (eds.), C.C. Thomas, Springfield, Chapter 9, pp. 219-238, 1969 (with T. Itil, D. Shapiro, N. Kiremitci, C. Hickman).
114. On-line computer classification of electroencephalographic sleep stages. *Psychophysiology* 4: 366 (with T. Itil, D. Shapiro, C. Hickman, N. Kiremitci and J.M.C. Holden). (abstract).
115. Cyclazocine and Methadone in narcotic addiction. *J.A.M.A.*, 202: 191-194 (with A.M. Freedman, R. Sharoff and A. Zaks).
- 116a. Social class and prognosis of schizophrenia. *Turk. Noro-Psikiyatri Arsivi*, 4: 1-12. (with N. Freilich, T. Itil).
- 116b. ...ibid., The influence of family structure and attitudes on the course and prognosis of schizophrenia, 5: 1-10, 1968 (with N. Freilich, T. Itil, J. M. Holden).

1968

117. Neurophysiological Response Strategies in the Classification of Mental Illness in *The Role of Methodology of Classification in Psychiatry and Psychopathology*, Katz, M.M., Cole, J.O., and Barton, W.E. (eds.), Washington, DC Govt. Printing Office, pp. 535-540.
118. Long acting Phenothiazine (Fluphenazine Decanoate) in the treatment of psychosis. *Arch. Gen. Psychiat.*, 18: 477-481 (with A. Keskiner, J. Simeon, and T.M. Itil).
119. Clinical Studies of Cyclazocine in the Treatment of Narcotic Addiction. *Amer. J. Psychiat.*, 124: 1499-1504 (with A.M. Freedman, R. Sharoff, and A. Zaks).
120. Naloxone in heroin dependence. *Clin. Pharm. Therap.*, 9: 568-577 (with A. Zaks, R. Sharoff, A. Mora, A. Bruner, S. Levit, A.M. Freedman).
121. Basic concepts and use of Cyclazocine in the treatment of narcotic addiction. *Brit. J. Addict.*, 63: 59-69 (with A.M. Freedman).
122. Differentiation of psychotropic drugs by quantitative EEG analysis. *Agressologie*, 9: 267-280, 1968 (with T. Itil, D. Shapiro).
123. Thioridazine and Chlordiazepoxide, alone or combined, in the treatment of chronic schizophrenia. *Comp. Psychiat.*, 9: 633-643 (with J. Holden, T. Itil, A. Keskiner).

124. EEG classification of psychoactive compounds in man: review and theory of behavioral associations. *Psychopharmacology: A Review of Progress, 1957-1967*: D. Efron, J. Cole, J. Levine and J.B. Wittenborn (eds.): U.S. Govt. Printing Office, Washington, DC, pp. 497-507.

1969

127. The human electroencephalogram: index of clinical activity of new psychoactive agents. *Mod. Prob. Pharmacopsychiat.*, 2: 106-110.

128. EEG and human psychopharmacology. *Ann. Rev. Pharmacol.*, 9: 241-258.

129. Psychoactive drugs and the alert human EEG. *Pakistan Medical Review* 3: 29-40.

130. Digital computer classifications of EEG sleep states. *Electroenceph. Clin. Neurophysiol.* 27: 76-83 (with T. Itil, D.M. Shapiro, D. Kassebaum).

131. Intravenous Diacetylmorphine (Heroin) in studies of opiate dependence. *Dis. Nerv. Syst. Suppl.*, 30: 89-92 (with A. Zaks, A. Bruner, A. Freedman).

132. High dose Chlordiazepoxide therapy of anxiety. *Curr. Therap. Res.*, 11: 9-14 (with M. Taylor, M. Spero, J. Simeon).

133. Liquid Butaperazine response in the treatment of chronic psychosis in a mental health clinic. *Curr. Therap. Res.* 11: 57-63 (with G. Clare, J. Simeon,).

134. High dose Tybamate therapy of heroin dependence. *J. Clin. Pharmacol. New Drugs.* 9: 232-238 (with F. Veress, V. Major, A. Freedman).

135. Narcotic antagonists and substitutes in opiate dependence. *The Present Status of Psychotropic Drugs*. A. Cerletti and F.J. Bove (eds.), *Excerpta Med. Fdn., Amsterdam*, 428-431 (with A. Freedman, A. Zaks, R. Sharoff, R. Resnick).

136. Clinical and EEG studies of Doxepin: an interim report. *Psychosomatics*, 10: 14-17 (with J. Simeon, M. Spero).

137. High and very high dose Fluphenazine in the treatment of chronic psychosis. In *The Present Status of Psychotropic Drugs*, A. Cerletti and F. J. Bove (eds.), *Excerpta Med. Fdn., Amsterdam*, 495-497 (with N. Polvan, V. Yagcioglu, T. Itil).

138a. EEG Patterns as an index of clinical activity of psychoactive drugs. *Electroenceph. Clin. Neurophysiol.*, 27: 710 (with D.M. Shapiro). (abstract).

138b. Drugs, EEG and behavior. *Drugs and the Brain*, P. Black (Ed.), Baltimore, Johns Hopkins Press, Chapter X, pp. 149-160.

139. Electroencephalograms, mental state and psychoactive drugs. *Pharmacol. for Physicians*. W.B. Saunders, Philadelphia, 3 (5): 1-5.

140. Electroencephalographic effects of Trifluoperidol. *Dis. Nerv. Syst.*, 30: 524-540 (with T. Itil).

141. EEG Patterns of Cyclazocine, a narcotic antagonist. In *Neurophysiological and Behavioral Aspects of Psychotropic Drugs*, A. Karczmar and W.P. Koella (eds.), C.C. Thomas, Philadelphia, Chapter 4, pp. 62-71

(with T. Itil, A. Zaks, A.M. Freedman).

142. Neuropharmacological analysis of agonistic actions of cyclazocine in rabbits. *Biol. Psychiat.*, 1: 217-330 (with R.P. White, W.G. Drew).

143. Anxiety precipitated by lactate. *New Eng. J. Med.*, 281:1429 (with M.A. Taylor and J. Volavka). (letter).

1970

144. Antagonists in the treatment of opiate dependence. In *Modern Trends in Drug Dependence and Alcoholism*, R.V. Phillipson, (ed.), Butterworth, London, pp. 49-59 (with A.M. Freedman).

145. Clinical antidepressant activity of Cyclazocine: a narcotic antagonist. *Clin. Pharmacol. Therap.*, 11: 41-48 (with J. Simeon, T. Itil, and A.M. Freedman).

146. A Cyclazocine typology in opiate dependence. *Amer. J. Psychiat.*, 126: 1256-1260 (with R. Resnick, A.M. Freedman).

147. d-Cycloserine therapy of psychosis by symptom provocation. *Comprehens. Psychiat.* 11: 80-88 (with J. Simeon, T. Itil, D. Ponce).

148. A comparison of Doxepin and Chloridiazepoxide in the therapy of anxiety. *Curr. Therap. Resch.*, 4: 201-211 (with J. Simeon, M. Spero, O. Nikolovski).

149. Depot Fluphenazine facilitation of treatment of psychosis. In *Changing Patterns in Psychiatric Care*, T. Rothman (ed.), Crown, N.Y., 176-185 (with J. Simeon, A. Keskiner, T.M. Itil).

150. Narcotic antagonists in opiate dependence. *Science*, 169: 1005-1006.

151a. Blockade with Methadone, Cyclazocine and Naloxone. *Int. J. Addictions*, 5: 507-515 (with A.M. Freedman, A. Zaks, R. Resnick).

151b. ...ibid., In Einstein, S. *Methadone Maintenance*, New York, M. Dekker, 161-170, 1971.

152a. Treatment of heroin dependence with opiate antagonists. In Masserman, J. (ed.), *Current Psychiatric Therapies*, Grune and Stratton, N.Y., 161-170 (with A. Zaks, R. Resnick and A.M. Freedman).

152b. ...ibid., In R.M. Suinn and R.G. Weigl (eds.): *Innovative Medical Psychiatric Therapies*. Baltimore, University Park Press, 51-60, 1976.

153. Electrographic effects of Diacetylmorphine Heroin and Naloxone in man. *Neuropharm.*, 9: 587-593 (with J. Volavka, A. Zaks, J. Roubicek).

154. Technology in psychiatric research. In S. Merlis (Ed.): *Non-Scientific Constraints in Medical Research*, Raven Press, New York, pp. 91-96.

155a. Lateralized EEG changes after induced convulsions. *Electroenceph. Clin. Neurophysiol.*, 29: 324 (with J. Roubicek, J. Volavka, R. Abrams). (abstract).

155b. Lateralized EEG changes after unilateral and bilateral electroconvulsive therapy. *Dis. Nerv. Syst.*, 31 (11) Suppl.: 28-33 (with R. Abrams, J. Volavka, J. Roubicek, R. Dornbush).

1971

156. Depot Fluphenazine in the treatment of psychosis in a community mental health clinic. *Dis. Nerv. Syst.*, 31 (9) Suppl.: 28-31 (with L. Bucci, M. Fuchs, J. Simeon).
157. Long-acting depot Phenothiazines in emergency and maintenance therapy of psychosis. In *The Role of Drugs in Community Psychiatry*, C. Shagass (ed.), Karger, Basel. *Mod. Probl. Pharmacopsychiat.*, 6: 78-82.
158. Memory changes after unilateral and bilateral convulsive therapy. *Brit. J. Psychiat.*, 119: 75-78 (with R. Dornbush, R. Abrams).
159. Naloxone treatment of opiate dependence. *JAMA*, 215: 2108-2110 (with A. Zaks, T. Jones, A.M. Freedman).
160. Opiate antagonists in the treatment of Heroin dependence in man. In *Narcotic Drugs, Biochemical Pharmacology*, Clouet, D. (ed.), Plenum Publ. Co., New York, pp. 468-477 (with A. Zaks, R. Resnick, and A. M. Freedman).
161. ...ibid., *Electrophysiological Studies of Opiates and Antagonists in Man*, pp. 452-467 (with A. Zaks, J. Volavka, J. Roubicek).
- 162a. A rational therapy of opiate dependence: narcotic antagonists. *Amer. J. Nursing*, 71: 1359-1363 (with A.M. Freedman, A. Zaks, R. Resnick).
- 162b. ...ibid., In *The Nurse in Community Mental Health*, E. P. Lewis and M. H. Browning (eds.), New York, Amer. J. Nursing Co., 283-293, 1972.
- 162c. ...ibid., *J. Psychedelic Drugs*, 4: 157-161.
163. Narcotic antagonists in the treatment of opiate dependence. *Int. Z. Klin. Pharm. Therap. u. Tox.*, 4: 455-458 (with A. Zaks, R. Resnick, A.M. Freedman).
164. Toward a rational theory of behavior. *Career Directions in Psychiatry*; 1: 22-29.
165. *Computer Aided Interactive Psychiatric Diagnosis Programs*. New York, Biodata, Inc., 75 pp. (with D. M. Shapiro, S. Feldstein).
- 166a. Marijuana, memory and perception. *Amer. J. Psychiat.* 128: 194-198 (with R. Dornbush, A.M. Freedman).
- 166b. ...ibid., In E.L. Abel (ed.): *Marijuana, Memory and Perception*. New York, MSS Information Corp., 23-26, 1973.
167. Marijuana, EEG and behavior. In *Marijuana: Chemistry, Pharmacology, and Patterns of Social Use*. A. Singer and S. Yolles (eds.), *Ann. N.Y. Acad. Sci.*, 191: 206-215 (with J. Volavka, R. Dornbush, S. Feldstein, G. Clare, A. Zaks, A. Freedman).
168. Cyclazocine therapy of opiate dependence: a progress report. *Comprehens. Psychiat.*, 12: 491-502 (with R. Resnick, A.M. Freedman).
- 169a. EEG profile analysis for psychopharmacology: a progress report. *Electroenceph. Clin. Neurophysiol.* 31: 105 (with D.M. Shapiro). (abstract).

- 169b. Discussion, quantitative EEG. *Clin. Electroenceph.*, 2: 116 (letter).
170. Evidence for a characteristic EEG frequency response to Thiopental. *Electroenceph. Clin. Neurophysiol.* 31: 149-153 (with J. Schwartz, S. Feldstein, D.M. Shapiro, and T. Itil).
171. EEG profiles of Fenfluramine, Amobarbital and Dextroamphetsmine in normal volunteers. *Psychopharmacologia Berl.* 22: 369-383 (with D.M. Shapiro and T.M. Itil).
172. Drugs and cerebral function, W.C. Smith (ed.), Book review, *Electroenceph. Clin. Neurophysiol.*, 31: 195.
173. Duration of methadone induced cross-tolerance to heroin. *Br. J. Addict.*, 66: 205-208 (with A. Zaks, A.M. Freedman).
174. An author seduced? Book review, *Seduction, A Conceptual Model in the Drug Dependencies and Other Contagious Social Ills*, P. Blachly. *Contemp. Psychol.*, 16: 721.

1972

175. *Convulsive Therapy* (ed.). *Seminars in Psychiatry* 4: 1. Grune & Stratton, Inc., New York, 70 pp.
176. The therapeutic process in induced convulsions ECT. *Seminars in Psychiatry*, 4: 39-46.
177. Answers to questions about ECT. *Seminars in Psychiatry*, 4: 33-38 (with R. Abrams).
178. CNS Effects of convulsive therapy: significance for a theory of depressive psychosis. In J. Zubin and F. Freyhan (eds.): *Disorders of Mood*, John Hopkins, Baltimore, pp. 93-112.

- 179a. EEG and clinical change after bilateral and unilateral electroconvulsive Therapy. *Electroenceph. Clin. Neurophysiol.*, 32: 631-639 (with J. Volavka, S. Feldstein, R. Abrams).
- 179b. ...*ibid.*, 32: 251-252. (abstract).
180. Clinical experiences with multiple electroconvulsive treatments. *Comprehens. Psychiat.*, 13: 115-121 (with R. Abrams).
181. Unilateral and bilateral ECT: effects on depression, memory and the electroencephalogram. *Arch. Gen. Psychiat.* 27: 88-94 (with R. Abrams, R.L. Dornbush, S. Feldstein, J. Volavka, J. Roubicek).
- 182a. A rational therapy of opiate dependence: narcotic antagonists. In C.J.D. Zarafonitis (ed.), *Drug Abuse: Proceedings of the International Conference*, Lea & Febiger, Philadelphia, 171-176.
- 182b. ...*ibid.*, Discussion, 177-188.
183. Clinical status of the narcotic antagonists in opiate dependence. In H. Kosterlitz, H.O.J. Collier, and J. Villareal (eds.): *Agonist and Antagonist Actions of Narcotic Analgesic Drugs*, London, MacMillan, pp. 266-276 (with A. Freedman, R. Resnick, and A. Zaks).
184. Opiate dependence: treatment and prophylaxis. In H.M. van Praag (ed.): *Biochemical and Pharmacologic Aspects of Dependence and Reports on Marijuana Research*, Amsterdam, Ervin F. Bohn, pp. 85-99.
185. ...*ibid.*, Cannabis psychosis, 194-204 (with A.M. Freedman).
186. Selective drug therapies in clinical psychiatry: neuroleptic, anxiolytic, and antimanic Agents. In *Treating Mental Illness: Aspects of Modern Therapy*, A. M. Freedman and H. Kaplan, (eds.), New York, Atheneum, pp. 287-309 (with R. Abrams).
187. Levomethadyl in maintenance treatment of opiate dependence. *JAMA*, 220: 811-813 (with A. Zaks, A.M. Freedman).
188. Treatment and prevention of opiate dependence with narcotic antagonists. *Contemp. Drug Probl.* 1: 245-262.
189. EEG effects of drug of dependence. In S.J. Mule and H. Brill (eds.). *Clinical and Biological Aspects of Drug Dependence*, Cleveland, Ohio, Chemical Rubber Co., 379-387.
190. EEG indices of CNS bioavailability of psychoactive drugs. *Electroenceph. Clin. Neurophysiol.*, 33: 246-247 (with D. M. Shapiro). (abstract).
191. Clinical evaluation of GP-41299: an antianxiety agent of the Doxepin type. *Arzneimittel-Forschung*, 22: 1903-1905 (with P. Gaztanaga, R. Abrams, J. Simeon, T. Jones).
192. Heroin maintenance. *JAMA*, 221: 602. (letter).
193. Heroin maintenance. *Contemp. Drug. Probl.*, 1: 875-877.
194. Effects of delta-nine-tetrahydrocannabinol on EEG, heart rate, and mood. *Electroenceph. Clin. Neurophysiol.* 33: 453 (with J. Volavka, R. Dornbush, S. Feldstein). (abstract).

195. 21-day administration of marijuana in male volunteers. In M. F. Lewis (ed.): *Current Research in Marijuana*, pp. 115-128, New York, Academic Press (with R.L. Dornbush, G. Clare, A. Zaks, P. Crown, J. Volavka).

1973

196. Quantitative EEG classification of psychoactive drugs in Man. In U.J. Jovanovic (ed.), *The Nature of Sleep*, Stuttgart, G. Fisher, pp. 76-78.

197. Methadone relatives and substitutes. *J.A.M.A.*, 223: 80. (letter).

198. The electroencephalogram in clinical psychiatry. In J. Mendels (ed.): *Biological Psychiatry*, J. B. Lippincott, N.Y. pp. 331-344.

199. EEG seizure patterns during multiple unilateral and bilateral ECT. *Comprehens. Psychiat.*, 14: 25-28 (with R. Abrams, J. Volavka).

200. Prediction of clinical response to ECT. *Brit. J. Psychiatry*, 122: 457-461 (with R. Abrams, S. Feldstein).

201. Heroin maintenance, panel discussion. *Contemp. Drug. Probl.*, 2: 165-200.

202. Drugs, EEG, and behaviour: EEG profiles and bioavailability measures for clinical psychopharmacology. *Electroenceph. clin. Neurophysiol.*, 34: 754. (abstract).

203. EEG, heart rate and mood change "high" after cannabis. *Psychopharmacologia*, 32:11-25 (with J. Volavka, P. Crown, R. Dornbush, S. Feldstein).

204. Psychological differentiation and the response of opiate addicts to pharmacological treatment. *Brit. J. Addic.*, 68: 151-157 (with S. Feldstein, P. Chester).

205. Narcotic antagonists. In National Commission on Marijuana and Drug Abuse, *Drug Use in America: Problem in Perspective*, Washington, DC, U.S. Government Printing Office, Appendix, IV: 143-157.

206. Levomethadyl Acetate: prolonged duration of opioid effects, including cross-tolerance to heroin, in man. *J.A.M.A.*, 226: 316-318 (with R. Levine, A. Zaks, A.M. Freedman).

207. Levomethadyl (LAAM): a long-acting substitute for methadone in maintenance therapy of opiate dependence. In J. Masserman (ed.), *Current Psychiatric Therapies*, XIII:151-155. New York, Grune & Stratton.

208. How shocking is shock therapy? Editorial, *Biological Psychiatry*, 7: 79-80.

209. Drug models in schizophrenia. In J. O. Cole, A. M. Freedman, and A. J. Friedhoff (eds.), *Psychopathology and Psychopharmacology*, Baltimore, Johns Hopkins Press, 1973, pp. 108-111.

210. Effects of cannabis on human EEG and heart rate: evidence of tolerance development on chronic use. In T.A. Ban, et al. (eds.), *Psychopharmacology, Sexual Disorders, and Drug Abuse*. Prague, Avicenum, pp. 703-704.

211. Questions in Cyclazocine therapy of opiate dependence. In S. Fisher and A. M. Freedman (eds.), *Opiate Addiction: Origins and Treatment*. Washington, DC, V. H. Winston and Sons, pp. 203-210.

1974

212. *Psychobiology of Convulsive Therapy*. Washington, DC, V.H. Winston and Sons (with S. Kety, J. McGaugh, and T. Williams (eds.)), 312 pp.
213. ...*ibid.*, Induced seizures and human behavior, pp. 1-18.
214. ...*ibid.*, Clinical progress in convulsive therapy, pp. 271-278.
215. EEG applications in psychopharmacology. In M. Gordon (ed.), *Psychopharmacological Agents Vol. III*. Academic Press, New York, pp. 159-174.
216. Simultaneous tactile perception in patients with conversion sensory deficits. *J. Mt. Sinai Hosp.*, 41:141-143 (with M.A. Green).
217. High dose Cyclazocine therapy of opiate dependence. *Amer. J. Psychiat.* 131: 595-597 (with R. Resnick, A.M. Freedman).
218. Psychoactive drugs, brain function, and human behavior. *Proc. World Congress Psychiatry*, Amsterdam, Excerpta Medica, pp. 747-750.
- 219a. Brain function, verbal behavior, and psychotherapy. *Comprehensive Psychiatry*, 15: 257-266.
- 219b. ...*ibid.*, In R. Spitzer and D.F. Klein (eds.): *Evaluation of Psychological Therapies*. Baltimore, Johns Hopkins Press, 1976, pp. 74-88.
220. Induced seizures. Book review: *Neurochemistry of Cerebral Electroshock*, W.B. Essman. *Science*, 184: 789.
221. Book review: *International Rev. Neurobiology, Vol. 15. Electroenceph. Clin. Neurophysiol.* 36: 557-558, 1974.
222. Short-term effects of heroin on Man. *Arch. Gen. Psychiat.* 30: 677-684 (with J. Volavka, R. Levine, S. Feldstein).
223. EEG and task performance after heroin in post-addicts. *Electroenceph. Clin. Neurophysiol.* 37: 195-196 (with J. Volavka, R. Levine, M. Komlosi). (abstract).
224. EEG profiles and bioavailability measures of psychoactive drugs. In T. Itil (ed.): *Psychotropic Drugs and the Human EEG. Modern Problems in Pharmacopsychiatry*, Basel, S. Karger, pp. 76-98.
225. Polypeptide influences on attention, memory, and anxiety in man. *Pharmacol. Biochem. and Behavior*, 2: 663-668 (with L. Miller, A. Kastin, C.A. Sandman, W.T. Van Veer).
226. Psychiatric diagnosis: phenotypic or pathophysiologic? Editorial. *Biological Psychiatry* 9: 227-229.
227. Cerebral electromy in phase I assessment of psychoactive drugs. In W.B. Essman and L. Valzelli (eds.): *Current Developments in Psychopharmacology*, New York, Spectrum Publ., pp. 301-316.

228. Electrophysiologic measures for phase I psychopharmacology in man. In G. McMahon (ed.): *Principles and Techniques of Human Research and Therapeutics, vol. VIII: Psychopharmacological Agents*, Mt. Kisco, N.Y., Futura Publishing, pp. 19-30.

229. Marijuana, hashish, and Tetrahydrocannabinol-delta-9: effects on EEG, heart rate, and Mood. *J. Psycho. Res.* 10: 159 (with J. Volavka, P. Crown, R. Dornbush). (abstract).

1975

230. Narcotic antagonist therapy of opiate dependence. In R.W. Richter (ed.): *Medical Aspects of Drug Abuse*, New York: Harper and Row, pp. 160-166.

231. Public hysteria and medical practice. Letter. *JAMA* 232: 1126, 1975 (with L. Koran, M.G. Miller).

232. New strategies of psychotropic drug evaluation. In T. Vossenaar (ed.): *Proceedings of a Symposium on Depressive Illness*. Amsterdam. *Excerpta Medica*, pp. 44-54.

233. Clinical evaluation of narcotic antagonism in man. In S. Ehrenpreis and M. Neidle (eds.): *Methods in Narcotics Research*. New York, M. Dekker, pp. 337-346.

234. Book review: *Psychotropic Drugs and the Human EEG* (eds.T.M. Itil, S. Karger), Basel, 1974. *Comprehensive Psychiatry* 16: 499-500.

235. Fenmetozole DH-524: Euphoriant classified by cerebral electrometry *Curr. Therap. Res.* 18: 590-596 (with P. Irwin).

236. Prediction of clinical activity of drugs in man. In Sudilovsky A., Gershon, S. and Beer, B. (eds.) *Predictiveness in Psychopharmacology: Preclinical and Clinical Correlations*. New York, Raven Press, pp. 65-87.

237. ...ibid., EEG classification of a novel anorexigenic: PRF-36-CL, comparison with placebo, Dextroamphetamine, and Fenfluramine, 89-103 (with P. Irwin, and P. Sibony).

238. Cerebral electrometry: quantitative EEG applied to human psychopharmacology. In H. Kunkel and G. Dolce (eds.): *CEAN - Computerized EEG Analysis*. Stuttgart, G. Fischer, 271-288.

239. The effects of extreme high dosage Fluphenazine on resistant schizophrenics in two different countries. In T.M. Itil (ed.): *Transcultural Neuropsychopharmacology*. Istanbul, Bozak Press, 95-100 (with T. Itil, N.O. Polvan).

1976

240. Chronic hashish use and mental disorder. *Am. J. Psychiat.* 133: 225-227 (with C. Stefanis, A. Liakos, J. Boulougouris, A.M. Freedman).

241a. Quantitative EEG studies of marijuana, delta-nine-Tetrahydrocannabinol, and hashish in man. In M.C. Braude and S. Szara (eds.): *The Pharmacology of Marijuana*. New York, Raven Press, 383-391 (with J. Volavka, C.P. Panayioutopolis, and C. Stefanis).

241b. ...ibid., *Electroenceph. Clin. Neurophysiol.* 42: 430, 1977. (abstract).

242. Controlled clinical and quantitative EEG Studies of Triflubarzepam (ORF-8063) in patients with anxiety. *Curr. Therap. Res.* 19: 307-315 (with T. Itil, S. Akpınar, N. Polvan, M. Huque, and K. Sungerbey).
243. Antipsychiatrists and ECT. (letter). *Brit. Med. J.* 1: 280, Jan 31, 1976.
244. Concentration of 5-Hydroxyindoleacetic Acid, Homovanillic Acid, and Tryptophan in the cerebrospinal fluid of depressed patients before and after ECT. *Biol. Psychiat.* 11: 85-90 (with R. Abrams, W.B. Essman, M.A. Taylor).
245. Book review: *LSD: A Total Study*, S. Sankar. Westbury, New York, PJD Publications, 1975. *Amer. J. Psychiat* 133: 593-594.
246. Book review: *Safeguarding Psychiatric Privacy*, E.M. Laska and R. Blank (eds.), New York, John Wiley & Sons, 1975, *Amer. J. Psychiat.* 133: 726-727.
247. Pharmacokinetic analysis of quantitative EEG data. In *Rationality of Drug Development*. Amsterdam, Excerpta Medica #383, 177-180 (with P. Irwin and M. Gastpar).
248. Relation of EEG to blood levels of psychoactive drugs. In L. Gottschalk and S. Merlis (eds.): *Pharmacokinetics, Blood Levels, and Clinical Response*. New York, Spectrum Publications, 243-250 (with P. Irwin).
249. Blood levels and EEG effects of Diazepam and Bromazepam. *Clin. Pharm. Therap.* 20: 184-191 (with P. Irwin, R. Weinfeld, M. Schwartz, A. Conney).
- 250a. EEG and Blood Level Correlations for Psychoactive Drugs. In M. Matejcek and G.K. Schenk (eds.): *Quantitative Analyses of EEG*. Konstanz, Switzerland, AEG Telefunken, 119-126 (with P. Irwin).
- 250b. Electroencephalographic measures for pharmacodynamic analysis of psychoactive drugs in Man. In P. Deniker, C. Radouco-Thomas, and A. Villeneuve (eds.): *Neuropsychopharmacology*. Oxford, England, Pergamon Press, 1203-1207, 1978.
251. An empirical comparison of three EEG digital conversion techniques. In M. Matejcek and G.K. Schenk (eds.): *Quantitative Analysis of EEG*. Konstanz, Switzerland, AEG Telefunken, 379-394 (with P. Irwin).
252. *Chronic Cannabis Use*. Edited by R.L. Dornbush, A.M. Freedman and M. Fink, *Annals N.Y. Academy of Sciences*, 282: 430 pp.
253. Effects of acute and chronic inhalation of hashish, marijuana, and THC-delta-9 on brain electrical activity in man: evidence for tissue tolerance. In R. Dornbush, A. Freedman and M. Fink (eds.): *Chronic Cannabis Use. Annals N.Y. Academy of Sciences* 282: 387-398.
254. Summary. Chronic cannabis use. *Annals N. Y. Academy of Sciences* 282: 427-430.
- 255a. EEG and task performance after ACTH 4-10 in man. *Neuropsychobiology* 2: 293-290 (with W. Sannita, P. Irwin).
- 255b. EEG and behavioral effects of ACTH 4-10 in normal volunteers. *Electroenceph. Clin. Neurophysiol.* 50: 2-3, 1980 (with W. Sannita, P. Irwin). (abstract).

1977

256. CNS sequelae of EST: risks of therapy and their prophylaxis. In C. Shagass, S. Gershon and A. Friedhoff (eds.): *Psychopathology and Brain Dysfunction*. New York, Raven Press, 223-239.
257. EST: a special case in pharmacotherapy. In W.E. Fann, I. Karacen, A.D. Pokorny and R.C. Williams (eds.): *Phenomenology and Treatment of Depression*. New York, Spectrum Publications, 285-294.
258. The treatment of narcotic poisoning. In H.F. Conn (ed.): *Current Therapy*, 1977. Philadelphia, W.B. Saunders, 894-895 (with A. Zaks).
259. Hypothalamic peptides and brain function. In E. Usdin, D. Hamburg, and J. Barchas (eds.) *Neuroregulators and Psychiatric Disorders*. New York, Oxford Press, 296-298.
260. *Hashish: A Study of Long-Term Use*. C. Stefanis, R. Dornbush, and M. Fink (eds.). New York, Raven Press, 181 pp.
261. ...ibid., Medical studies in long-term hashish users. II. Clinical electroencephalography and echoencephalography, 59-62 (with C.P. Panayiotopoulos, J. Volavka, C. Stefanis).
262. ...ibid., Acute EEG effects of cannabis preparations in long-term users, 79-90 (with J. Volavka, C.P. Panayiotopoulos).
263. ...ibid., Study of long-term hashish users in Greece: Summary and Discussion, 151-158.
264. Book review: *Marihuana Chemistry, Biochemistry, and Cellular Effects*. G.C. Nahas, W.D.M. Paton, and J.E. Idanpaan-Heikkila (eds.). New York, Springer-Verlag, 1976. *Quart. Rev. Biol.* 52: 236.
265. Quantitative EEG analysis and psychopharmacology. In Remond, A. (ed.): *EEG Informatics. A Didactic Review of Methods and Applications of EEG Data Processing*. Amsterdam, Elsevier, 301-308.
266. EEG, blood level, and behavioral effects of the antidepressant Mianserin (Org GB 94). *Psychopharmacologia* 54: 249-254 (with P. Irwin, M. Gastpar, and H. de Ridder).
267. Myths of "shock therapy." *Amer. J. Psychiat.* 134: 991-996.

1978

268. Comments on report by P. Simon. In P. Deniker, C. Radouco-Thomas, and A. Villeneuve (eds.): *Neuropsychopharmacology*. Oxford England, Pergamon Press, 215-217.
269. Psychoactive drugs and the waking EEG. In M.A. Lipton, A. DiMascio, and K.F. Killam (eds.): *Psychopharmacology: A Generation of Progress*. New York, Raven Press, 691-698.
270. EEG response strategies in psychiatric diagnosis. In Spitzer, R. and D.F. Klein (eds.): *Critical Issues in Psychiatric Diagnosis*. New York, Raven Press, 253-263.
271. EEG study of Mianserin (GB-94) in depressed patients. *Brit. J. Clin. Pharmacol.* 5 Supplement (1): 43S-49S (with P. Irwin).

272. Sieben jahre klinische erfahrung mit opiat-antagonisten bei Opiatabhangigkeit. In W.F. Biniek (ed.): *Drogenabhangigkeit*. Darmstadt, Wissenschaftliche Buchgesellschaft, 422-431.
273. Efficacy and safety of induced seizures (EST) in man. *Comprehens. Psychiat.* 19: 1-18.
274. ECT in metropolitan New York hospitals: A survey of practice 1975-1976. *Amer. J. Psychiat.* 135: 479-482 (with G.M. Asnis, S. Saferstein).
275. Is EST a useful therapy of schizophrenia? In J.P. Brady and H.K.H. Brodie (eds.): *Controversy in Psychiatry*. Philadelphia, W.B. Saunders Co., 183-193.
276. Electroshock therapy: myths and realities. *Hosp. Pract.* 13: 77-82.
277. EEG and psychopharmacology. In Cobb, W.A. and van Duijn, H. (eds.): *Contemporary Clinical Neurophysiology Suppl. 34, Electroenceph. Clin. Neurophysiol.* 45: 41-56.
278. Book review: *Neuropeptide Influences in the Brain and Behavior*. *Adv. Biochem. Pharmacol.* 17: L.H. Miller, C.A. Sandman and A.J. Kastin (eds.), New York, Raven Press, 298 pp, 1977. *Quart. Rev. Biol.* 53: 195.
279. Book review: *Psychopharmacology. A Biochemical and Behavioral Approach*. L.S. Seiden and L.A. Dykstra (eds.), New York, Van Nostrand Co., 451 pp., 1977. *Quart. Rev. Biol.* 53: 196.
280. Book review: *Psychotherapeutic Drugs. Part 1: Principles. Part 2: Applications*. E. Usdin and I.S. Forrest (eds.), New York, Marcel Dekker, 698+699 pp., 1976. *Quart. Rev. Biol.* 53: 210-211.
281. Book review: *Hemi-Inattention and Hemisphere Specialization*. E.A. Weinstein and R.P. Friedland (eds.), New York, Raven Press, 156 pp., 1977. *Quart. Rev. Biol.* 53: 211.

1979

- 282a. *Convulsive Therapy: Theory and Practice*. New York, Raven Press, 308 pp.
- 282b. *Convulsive Therapy: Theory and Practice*. Published in Japanese translation, Tokyo, Seiwa Shoten, 394 pp., 1980.
283. Mania and electroseizure therapy (EST). In Shopsin, B. (ed.): *Manic Illness*. New York, Raven Press, 219-228.
284. A history of convulsive therapy. *Psych. Jrl. Univ. Ottawa Fac. Med.* 4: 105 - 110.
285. Efficacy of ECT. *Lancet* 2: 1303 -1304. (letter).
286. EST and other somatic therapies of schizophrenia. In L. Bellak (ed.): *Disorders of the Schizophrenic Syndrome*. Basic Books, New York, 353-363.
287. CNS effects of the antihistamines, Diphenhydramine and Terfenadine RMI-9918. *Pharmakopsych. Neuro-Psychopharmakologie* 12: 35, 44 (with P. Irwin).
- 288a. Phenytoin: EEG effects and plasma levels in volunteers. *Therap. Drug Monitoring* 1: 93-104 (with P. Irwin, W. Sannita, Y. Papakostas, M.A. Green).

- 288b. EEG study of phenytoin in normal volunteers at non-toxic doses. *Electroenceph. Clin. Neurophysiol.* 49: 83 (abstract).
- 289a. EEG profile studies of clozapine in volunteers and psychiatric patients. *Pharmakopsych. Neuro-Psychopharmakologie* 12: 184-190 (with P. Irwin and P. Weinhold).
- 289b. EEG effects of clozapine: Association or dissociation of EEG and behavior? *Neuro-Psychopharmacology*. Oxford, Pergamon, 363-369. (abstract).
290. Anxiety, anxiolytics and the human EEG. In w. Fann, I. Karacen, A. Pokorny, and R.L. Williams, (eds.): *Phenomenology and Treatment of Anxiety*. New York, Spectrum Publications, 237-250.
291. Neurobiology Group Report, Dahlem Conference. In K.S. Fu and T. Pavlidis (eds.): *Biomedical Pattern Recognition and Image Processing. Life Sciences Research Report 15*. Verlag Chemie, Basel, 364-394 (with D.B. Cooper, M. Abeles, G. Bodenstein, et al.).
292. Normal prolactin responses in tardive dyskinesia. *Psychopharmacology* 66: 247-250 (with G.M. Asnis, E.J. Sachar, G. Langer, F.S. Halpern).
293. Book review: *Contemporary Research in Behavioral Pharmacology*. D.E. Blackman and D.J. Sanger (eds.), New York, Plenum Press, 506 pp., 1978. *Quart. Rev. Biol.* 54:118-119.
294. Book review: *The Endorphins. Adv. Biochem. Pharmacol.* 18. E. Costa and M. Trabucchi (eds.), New York, Raven Press, 379 pp., 1978. *Quart. Rev. Biol.* 54: 119.
295. Book review: *Rational Anti-epileptic Drugs Therapy*. P.J.M. Guelen and E. van der Kleijn. Amsterdam, Elsevier/North Holland. *Trends in Neurosciences* 2: 492-494.
296. Book review: *Psychotropic Drugs: A Guide for the Practitioner*. H.M. van Praag, New York, Brunner/Maxel, 1978. *Comprehens. Psychiat.* 20 :494-495.

1980

- 297a. A neuroendocrine theory of convulsive therapy. Point of view. *Trends in Neurosciences* 3: 25-27.
- 297b. ...ibid. *Nervenheilkunde* 1: 26-29, 1982.
- 297c. Convulsive therapy and depression: A neurohumoral and neuroendocrine theory. In Saletu, B. (ed.): *Neuro-Psychopharmacology*. Oxford, Pergamon, 41-44. (abstract).
- 297d. A theory of convulsive therapy in endogenous depression: Significance of hypothalamic functions. *Psychiatry Research* 2: 49-61 (with J.O. Ottosson),
298. Convulsive therapy and endogenous depression. *Pharmakopsychiat.* 13: 49-54.
299. Neuroendocrinology and ECT: A review of recent developments. *Comprehens. Psychiat.* 21: 450-459.
300. ECT, mood and hormones. In D. de Wied and P. A. van Keup (eds.): *Hormones and the Brain*. MTP Press, Lancaster, England, 253-262.
301. Convulsive and drug therapies of depression. *Ann. Rev. Med.* 32: 405-412.

302a. Neuroendocrine measures in psychiatric patients: Course and outcome with ECT. *Psychiatry Research* 4: 55-64 (with Y. Papakostas, J. Lee, P. Irwin, L. Johnson).

302b. Dexamethasone suppression test and outcome with ECT. In C. Perris, G. Struwe, and B. Jansson (eds.): *Biological Psychiatry* 1981. 1075-1078, 1981.

303. Random thoughts about ECT. (editorial). *Am. J. Psychiat.* 138: 484-485.

1981

304. Toward a rational theory of behavior. *Career Directions* 7: 2-12.

305. An objective classification of psychoactive drugs. *Prog. Neuro-Psychopharm.* 4: 495-502.

306. EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug. *Psychopharmacology* 72: 67-71 (with Peter Irwin).

307. EEG and behavioral effects of pirenzepine in normal volunteers. *Scand. Jrl. Gastroenterol.* 15 Supplement 66: 39-46 (with Peter Irwin).

308. Classification of psychotropic drugs: Quantitative EEG analysis in man. In van Praag, H.M., Lader, M.H., Rafaelson, O.J. and Sachar, E.J. (eds.): *Handbook of Biological Psychiatry*. Volume VI. Marcel Dekker, New York, 309-326.

309. The significance of quantitative pharmaco-electroencephalography in establishing dose-time relations and its impact on clinical pharmacology: Critical review and perspectives. *Psychopharm. Bull.* 17:94. (abstract).

310a. Lateral cerebral differences in psychotropic drug effects. *Psychopharm. Bull.* 17:98. (abstract). (with Peter Irwin).

310b. Do psychoactive drugs affect the EEG from the cerebral hemispheres differently? In C. Perris, D. Kemali and L. Vacca (eds.): *Electroneurophysiology and Psychopathology*. S. Karger, Basel, Adv. Biol. Psychiat 6: 121-125 (with P. Irwin).

311a. Critical flicker-fusion frequency, EEG, and psychoactive drugs. *Psychopharm. Bull.* 17: 103. (abstract). (with P. Irwin).

311b. EEG, CFF and behavior. *Pharmakopsychiatria* 15: 36-38, 1982 (with P. Irwin).

312. A single measure of EEG spectral differences with heuristic value in assessing drug effect. *Electroenceph. Clin. Neurophysiol.* 51: 32P (abstract). (with P. Irwin).

313. CNS effects of clonidine in normal volunteers. *Psychopharm. Bulletin.* 17: 16-17 (with P. Irwin).

314. Pharmaco-EEG and bioequivalence: A practical methodology for psychoactive drugs. *Psychopharm. Bulletin* 17: 120-121.

315. Pharmacoelectroencephalographic study of brotizolam, a novel hypnotic. *Clin. Pharm. Therap.* 30: 336-342 (with P. Irwin).

316. EEG and behavioral effects of aspirin in asymptomatic volunteers. In C. Perris, G. Struwe, and B. Jansson (eds.): *Biological Psychiatry* 1981, Elsevier, Amsterdam, 227-229 (with P. Irwin)
317. Clinical trials with des-Tyr-gamma-Endorphin GK-78. In C. Perris, G. Struwe, and B. Jansson (eds.): *Biological Psychiatry* 1981, Elsevier, Amsterdam, 398-401 (with Y. Papakostas, J. Lee, T. Meehan, L. Johnson).
318. Book review: *The Psychosurgery Debate*. E. S. Valenstein (ed.). W.H. Freeman & Co., San Francisco, 1980. *Amer. J. Psychiat.* 138: 408-409.
- 319a. Book review: *Divergent Views in Psychiatry*. M. Dongier and E. D. Wittkower (eds.). Harper & Row, Hagerstown, MD, 1981. *Am. J. Psychiat.* 138: 1641.
- 319b. Divergent views of divergent views: Dr. Fink replies. (letter). *Am. J. Psychiat.* 139: 1219-1220, 1982.
320. Book review: *Neural Peptides and Neuronal Communication*. E. Costa and M. Trabucchi (eds.). Raven Press, New York, 1980. *Quart. Rev. Biol.* 56: 98.
321. Book review: *Differential Psychopharmacology of Anxiolytics and Sedatives*. J. R. Boissier (ed.). S. Karger, Basel, 1979. *J. Nerv. Ment. Dis.* 169: 469-470.
322. Book review: *The Psychodynamic Approach to Drug Therapy*. M. Ostow (ed.). Van Nostrand, Reinhold, New York, 1980. *Science Books and Films* 16: 209.
323. Book review: *Law and Ethics in the Practice of Psychiatry*. C.K. Hofling (ed.). Brunner/Mazel, 1981. *Science Books and Films* 17: 64-65.
- 1982**
324. Mianserin. In H. Lehmann (ed.): *Non-MAOI and Non-Tricyclic Antidepressants*. S. Karger, Basel. *Mod. Probl. Pharmacopsychiat.* 18: 70-101 (with R. Pinder).
325. Quantitative pharmaco-EEG to establish dose-time relations in clinical pharmacology. In W.M. Herrmann (ed.): *Electroencephalography in Drug Research*. Gustav Fischer, Stuttgart, 17-22.
- 326a. Guidelines for pharmaco-EEG studies in man. *Pharmacopsychiat.* 15:107-108 (with G. Stille, W.M. Herrmann, D. Bente, T.M. Itil, W.P. Koella, S. Kubicki, H. Kunkel, J. Kugler, M. Matejcek and Petsche, H.).
- 326b. ...ibid., Empfehlungen für pharmakoelektroenzephalographische Untersuchungen am Menschen. *EEG-EMG* 13: 1-2.
327. Anticholinergic drugs and the EEG. In Committee on Toxicology, National Academy of Sciences. *Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents: I: Anticholinesterases and Anticholinergics*. National Academy Press, Washington, DC, June 1-8.
328. Neurophysiologic methods to establish antidepressant activity. Neurophysiologische Methoden zum Nachweis antidepressiver Wirkung. *Arzneimittelforschung* 32: 857-859.
329. CNS effects of acetylsalicylic acid Aspirin (with P. Irwin). *Clin. Pharm. Therap.* 32: 362-365.

- 330a. Pharmaco-EEG study of 6-azamianserin ORG-3770: Dissociation of EEG and pharmacologic predictors of antidepressant activity (with P. Irwin). *Psychopharmacology* 78: 44-48.
- 330b. ...*ibid.*, *Psychopharm. Bull.* 19: 96, 1983.
331. Blood levels and quantitative EEG response to CNS-active drugs: Retrospective observations. *Electroenceph. Clin. Neurophysiol. Suppl.* 36: 447-452 (with P. Irwin).
332. Predictors of outcome in convulsive therapy. *Psychopharm. Bull.* 18: 50-57.
333. Convulsive therapy: A risk-benefit analysis. *Psychopharm. Bull.* 18: 110-116.
334. Placebo-controlled studies of ECT. *Br. J. Psychiat.* 141: 213-214. (letter).
335. Neuroendocrine aspects of convulsive therapy. In R. Abrams and W. Essman (eds.): *Electroconvulsive Therapy: Biological Foundations and Clinical Applications*. Spectrum Publications, New York, 187-198.
- 336a. Monitoring the duration of ECT seizures: 'Cuff' and EEG methods compared (with L. Johnson). *Arch Gen. Psychiat.* 39:1189-1191.
- 336b. EEG monitoring of ECT preferred to cuff method. Reply. *Am. J. Psychiat.* 140: 1649, 1983.
- 336c. ECT Seizure Monitoring. *Arch. Gen. Psychiat.*: 106-107, 1984 (with L. Johnson). (letter).
337. The enigma of convulsive therapy: An effective, safe and controversial treatment. In J.O. Cavenar and H.K.H. Brodie (eds.): *Critical Problems in Psychiatry*. J. B. Lippincott, Philadelphia, 203-219.
338. ECT in the elderly. In C. Eisdorfer and W.E. Fann (eds.): *Treatment of Psychopathology in the Aging*. Springer Publishing Co., New York, Chapter 7, 97-111.
339. ECT in anxiety: An appraisal. *Am. J. Psychother.* 36: 371-378.
340. The present status of electroconvulsive therapy. *Directions in Psychiatry*. Hatherleigh Co. Ltd., New York, 35:1-8.
341. Book reviews: *ECT in Great Britain*. J. Pippard and L. Ellam: *Electroconvulsive Treatment in Great Britain*, 1980. Gaskell, London, 162 pp., 1981; and R. L. Palmer (ed.): *Electroconvulsive Therapy: An Appraisal*. Oxford, New York 316 pp., 1981. *Am. J. Psychiat.* 139:958-959.
342. Book review: *Drug Development Research*. H. Lal and S. Fielding (eds.). A.R. Liss, New York. *Quart. Rev. Biol.* 57: 234.

1983

343. Guidelines for electroconvulsive therapy in the elderly. In T. Crook and G. D. Cohen (eds.): *Physicians' Guide to the Diagnosis and Treatment of Depression in the Elderly*. Mark Powley Associates, New York, VI: 55-60.
344. Missed seizures and the bilateral-unilateral electroconvulsive therapy controversy. *Am. J. Psychiat.* 140: 198-199. (editorial).
345. Bias against ECT: again. *Contemp. Psychol.* 28: 246-247. (letter).

346. Antidepressant effects of electroconvulsive therapy. *Br. Med. J.* 286:1744-1745. (letter).
347. Electroshock and Berkeley: II. *Biol. Psychiat.* 18: 610-613. (editorial).
348. ECT and depression: What have we learned? In F.J. Ayd, I.J. Taylor, and B.T. Taylor (eds.): *Affective Disorders Reassessed: 1983*. Ayd Medical Communications, Baltimore, pp. 56-72.
349. Pharmacoelectroencephalography. *Neuropsychobiol.* 9: 45-46. (editorial). (with D. Bente and H. Kunkel).
350. Book review: *The Unfathomed Mind: A Handbook of Unusual Mental Phenomena*. W.R. Corliss. Glen Arm, MD, 754 pp., 1981. *Science Books and Films* 18: 242.
351. Book review: *Neurobiology*. G. M. Shepherd. Oxford University Press, NY, 611 pp., 1983. *Science Books and Films* 19: 83.
352. Book reviews: *Advances in Biochemical Pharmacology. Vol. 31. Typical and Atypical Antidepressants: Molecular Mechanisms. Vol. 32: Clinical Practice*. E. Costa and G. Racagni (eds.). Raven Press, N.Y. 391 pp. and 400 pp., 1982. *Non-Tricyclic and Non-Monoamine Oxidase Inhibitors*. H.E. Lehmann (ed.). S. Karger, Basel, 1982. *Quart Rev. Biol.* 58: 300-301.
- 1984**
353. Theories of the antidepressant efficacy of convulsive therapy ECT. In R.M. Post and J.C. Ballenger (eds.): *Neurobiology of Manic Depressive Illness*. Williams & Wilkins, Baltimore, 721-730.
354. Theories of convulsive therapy: A neuroendocrine hypothesis. In B. Lerer, R. Weiner, and R.H. Belmaker (eds.): *ECT: Basic Mechanisms*. John Libbey & Co., London, pp. 115-123.
- 355a. Convulsive therapy: Fifty years of controversy. *Clin. Neuropharmacol.* 7. Supplement 1: 8-9 (abstract).
- 355b. Meduna and the origins of convulsive therapy. *Am. J. Psychiat.* 141: 1034-1041.
356. Neuroendocrine aspects of the relief of melancholia by induced seizures ECT. In E. Usdin, M. Asberg, L. Bertilsson, and F. Sjoqvist (eds.): *Frontiers in Biochemical and Pharmacological Research in Depression*. *Adv. Biochem. Psychopharm.* 39: 345-357.
357. Pharmacology-EEG effects of antihypertensive agents. *Clin. Neuropharmacol.* 7 Supplement 1: 119 (abstract).
358. Familiarization session and the placebo control in EEG studies of drug effects. *Neuropsychobiology.* 10: 173-177 (with P. Irwin).
359. ECT: For whom is it justified? *J. Clin. Psychopharmacol.* 4: 303-304 (editorial).
360. The present status of unilateral ECT: Some recommendations. *J. Affect. Dis.* 7: 245-247 (editorial). (with R. Abrams).
361. Book review: L.B. Kalinowsky, H. Hippus, and H.E. Klein. *Biological Treatments in Psychiatry*. Grune & Stratton, New York, 424 pp., 1982. *Compr. Psychiatr.* 25: 126-127.

362. Book reviews: Vaillant, G. E. *The Natural History of Alcoholism*. Harvard Univ. Press, Cambridge, MA, 359 pp., 1983; B. Tabakoff, P.B. Sutker, and C.L. Randall (eds.): *Medical and Social Aspects of Alcohol Abuse*. Plenum Press, New York, 403 pp., 1983; R.G. Smart, F.B. Glaser, Y. Israel, H. Kalant, R.E. Popham, and W. Schmidt (eds.): *Research Advances in Alcohol and Drug Problems vol. 7*, Plenum Press, New York, 472 pp., 1983. *Quart. Rev. Biol.* 59: 369-370.

363. Book review: P. Carlton. *A Primer of Behavioral Pharmacology*. W. H. Freeman & Co., 301 pp., 1983. *Quart. Rev. Biol.* 59: 511-512.

1985

364. Pharmaco-electroencephalography: A note on its history. *Neuropsychobiology*. 1984; 12: 173-178.

365. Convulsive Therapy. *Convulsive Ther.* 1985; 1: 1-3. (editorial).

366. Reducing memory loss in electroconvulsive therapy. *Convulsive Ther.* 1985; 1: 77-80. (editorial).

367. A 'gratuitous' conclusion on ECT. *Am J Psychiatry* 1985; 142: 1129. (letter).

368. Anesthesia in electroconvulsive therapy. *Convulsive Ther.* 1985; 1: 155-157. (editorial).

369. Convulsive therapy: Fifty years of progress. *Convulsive Ther.* 1985; 1: 204- 216.

370. The ethics of placebo. In L. White, B. Tursky, G.E. Schwartz (eds.): *Placebo: Theory, Research and Mechanisms*. Guilford Press, New York, 1985; 423-430.

371. Anesthesia in ECT. *J Clin Psychopharmacol.* 1985; 5: 312. (letter).

372. MAOI, anesthesia, and ECT. *J Clin Psychopharmacol* 1985; 5: 313. (with K. Freese).

373. National Institutes of Health Consensus Conference on ECT. *Convulsive Ther.* 1985; 1: 231-233. (editorial).

374. Pharmaco-EEG as a method to assess bioequivalence of CNS active substances in man. *Integrative Psychiatry* 1985; 3 Supplement: 12S-19S.

375. Summary. *Integrative Psychiatry* 1985; 3 (Supplement): 92s-93s (with L. Hollister).

376. Book review. E.A. Turner. *Surgery of the Mind*. Carmen Press, Birmingham UK, 238 pp., 1982. In *Am J Psychiatry* 1985; 142: 374-375.

377. Book review. M. Fraser. *ECT: A Clinical Guide*. John Wiley, New York, 134 pp., 1982. In *Convulsive Ther* 1985; 1: 66-67.

378. Book review. N.S. Endler. *Holiday of Darkness: A Psychologist's Personal Journey Out of Depression*. Wiley-Interscience, New York, 169 pp., 1982. In *Convulsive Ther.* 1985; 1: 140-142.

379. Book reviews: L. Kalinowsky, H. Hippus, H.E. Klein. *Biological Treatments in Psychiatry*. Grune & Stratton, New York, 424 pp., 1982; R. Abrams, W.B. Essman (eds.): *Electroconvulsive Therapy: Biological Foundations and Clinical Applications*. Spectrum Publications, New York, 270 pp., 1982. In *Convulsive Ther.* 1985; 1: 222-223.

380. Book review: S.E. Luria. *A Slot Machine, A Broken Test Tube*. Harper & Row, New York, 230 pp., 1984. In *Am J Psychiatry* 1985; 142: 1210-1211.

381. Book review: G.G. Nahas. *Marijuana in Science and Medicine*. Raven Press, New York, 312 pp., 1984. In *Quart Rev Biol.* 1985; 60: 551-552.

382. Book review: R.G. Smart et al. (eds.): *Research Advances in Alcohol and Drug Problems*. Vol 8. Plenum Press, New York, 333 pp. In *Quart Rev Bioi* 1985; 60: 552.

385a. Historical Article: Autobiography of L. J. Meduna. *Convuls Ther.* 1985; 1(1): 43-57.

1986

383. Neuroendocrine predictors of ECT outcome: DST and prolactin. *Annals New York Academy Sci* 1986; 462: 30-36.

384. Convulsive therapy today: A decade of increased understanding and acceptance. *Psychiatry Letter* 1986; 4: 7-12.

385b. Autobiography of L.J. Meduna. *Ideggyogyaszati szemle* 1986; 39: 225-34. (article in Hungarian).

386. Electroconvulsive therapy today. *Currents* 1986; 5: 5-12. (interview).

387. Convulsive therapy and epilepsy research. In M.R. Trimble and E.H. Reynolds (eds.): *What is Epilepsy? The Clinical and Scientific Basis of Epilepsy*. Churchill Livingstone, Edinburgh, 1986, 217-228.

388. Serial dexamethasone suppression tests in ECT. *Clin Neuropharm* 1986; 9: Suppl. 4: 444-446 (with K. Gujavarty K, L. Greenberg). (abstract).

389. Multi-lead EEG dynamic mapping during ECT. *Clin Neuropharm* 1986; 9: Suppl. 4: 536-537 (with M. Fink, L. Greenberg, K. Gujavarty). (abstract).

390. Convulsive therapy: How it evolved. *Psychopharm Bull* 1986; 22: 357-459.

391. A new evaluation of convulsive therapy: The Ontario report. *Convulsive Ther* 1986; 2: 73-76 (editorial).

392. Training in ECT. *Convulsive Ther* 1986; 2: 227-230. (editorial).

393. Book review: J. Winson. *Brain and Psyche: The Biology of the Unconscious*. New York, Doubleday, 1985, 300 pp. In *Science Books and Films* 1986; 21: 157.

394. Book review: D.C. Horwell (ed.): *Drugs in the Central Nervous System Disorders*. New York, Marcel Dekker Inc. 1985, 354 pp. In *Quart Rev Biol* 1986; 61: 146.

1987

395. Serial dexamethasone suppression tests and clinical outcome in ECT. *Convulsive Ther* 1987; 3: 111-120 (with L. Greenberg, K. Gujavarty).
396. Electroconvulsive therapy and neuroleptic medication in the treatment of therapy resistant positive-symptom psychosis. *Convulsive Ther* 1987; 3: 185-195 (with K. Gujavarty, L. Greenberg).
397. Isoflurane anesthesia therapy: A replacement for ECT in depressive disorders? *Convulsive Ther* 1987; 3: 269-277 (with L.B. Greenberg, J. Gage, S. Vikun).
398. Update on ECT. *Psychiatric Annals* 1987; 17: 47-53 (interview).
399. Convulsive therapy in affective disorders: A decade of understanding and acceptance. In H. Meltzer (ed.): *Psychopharmacology: A Third Generation of Progress*. Raven Press, New York, 1987, Chap 108: 1071-1076.
400. ECT: A last resort treatment for resistant depression? In J. Zohar, R. Belmaker (eds.): *Treating Resistant Depression*. PMA Publishing Co, New York, Chap 9: 163-173.
401. Convulsive therapy. In G Adelman (ed.): *Encyclopedia of Neuroscience*. Birkhuser, Boston, 1987, 277-278.
402. Neuroendocrine aspects of convulsive therapy: Review of recent developments. In C.B. Nemeroff, P.T Loosen (eds.): *Handbook of Clinical Psychoneuroendocrinology*. Guilford Press, New York, 1987, Chapter 11: 255-265.
403. New technology in convulsive therapy: A challenge in training. *Am J Psychiatry* 1987; 144: 1195-1196 (editorial).
404. Neuropsychiatry and behavioral neurology. *Convulsive Ther* 1987; 3: 91-92 (editorial).
405. Is ECT usage decreasing? *Convulsive Ther* 1987; 3: 171-173. (editorial).
406. Maintenance ECT and affective disorders. *Convulsive Ther* 1987; 3: 249-250 (editorial).
407. Contraindications to electroconvulsive therapy. *Anesth Analg* 1987; 66: 918 (letter).
408. A case of resistant schizophrenia. *Br J Psychiatry* 1987; 150: 562-563 (letter).
409. Book review: A.V. Valdman (ed.): *Drug Dependence and Emotional Behavior: Neurophysiological and Neurochemical Approaches*. Plenum Publ Co., New York, 1986. In *Quart Rev Biol* 1987; 62: 120-121.
410. Book review: W. Kalow, H.W. Goedde, D.P. Agarwal (eds.): *Ethnic Differences in Reaction to Drugs and Xenobiotics*. AR Liss, New York, 583 pp., 1986. In *Quart Rev Biol* 1987; 62: 124.
411. Book review: M.H. Van Woert, E. Chung (eds.): *Cooperative Approaches to Research and Development of Orphan Drugs*. AR Liss, New York, 204 pp., 1985. In *Quart Rev Biol* 1987; 62: 124-125.

412. Book review: E.S. Valenstein. *Great and Desperate Cures*. Basic Books, New York, 338 pp., 1986. In *Convulsive Ther* 1987; 3: 79-81.

413. Book review: M. Brause, A.M. Zimmerman (eds.): *Genetic and Perinatal Effects of Abused Substances*. Academic Press, New York, 211pp., 1987. In *Quart Rev Biol* 1987; 62: 469.

1988

414. Prospective electroconvulsive therapy in delusional depressed patient with a frontal meningioma. *Br J Psychiatry* 1988; 153: 105-107 (with L.B. Greenberg, R. Mofson).

415. Convulsive therapy for affective disorders. In A. Georgeotas and R. Cancro (eds.): *Depression and Mania*. Elsevier, North Holland and New York, 1988; 29: 452-460.

416. Convulsive therapy: A manual of practice. *Review of Psychiatry VII*. 1988; 21: 482-497. APA Press, Washington DC.

417. The present status of electroconvulsive therapy: An update. F. Flach (ed.): *Directions in Psychiatry* 1988; 1-8. Hatherleigh Co., New York.

418. Forward. *Electroconvulsive Therapy*, Richard Abrams, 1st ed., Oxford University Press, New York, 1988; vii-x.

419. Forward. *Electroconvulsive Therapy: The Myths and the Realities*. N.S. Endler, E. Persad, Hans Huber, Toronto; 1988; ix-xi.

420. Fifty years of electro-convulsive therapy. *Convulsive Ther* 1988; 4: 2-4 (editorial).

421. ECT for Parkinson disease? *Convulsive Ther* 1988; 4: 189-191 (editorial).

422. How does ECT work? *Psychopharmacol Bull* 1988; 24: 385-386 (with W. Potter).

423. Neuroendocrine hypothesis of antidepressant action of ECT. *Psychopharmacol Bull* 1988; 24: 400-402.

424. Use of ECT in the United States. *Am J Psychiatry* 1988; 145: 133-134. (letter).

425. ECT instrumentation. *Biol Psychiatry* 1988; 24: 360-361. (letter).

426. The diagnosis and treatment of depression in the old. *JAMA* 1988; 260: 1405. (letter).

427. ECT: The continuing controversy. *Consensus in Psychiatry* 1988; 1: 1.

428. Brain imaging and pharmaco-EEG. *Consensus in Psychiatry* 1988; 1: 1-2.

429. Book review: Kurt Eissler: *Freud as an Expert Witness*. IUP Press, Madison CT, 1986. In *Convulsive Ther* 1988; 4: 250-251.

430. Book reviews: M.A. Taylor, F.S. Sierles, R. Abrams. *General Hospital Psychiatry*. Free Press, New York, 1985; A. Stoudemire, B.S. Fogel (eds.): *Principles of Medical Psychiatry*. Grune & Stratton, Orlando FL, 1987; A.J. Frances, R.H. Hales (eds.): *Review of Psychiatry VII*, American Psychiatric Press, Washington DC, 1988. In *Convulsive Ther* 1988; 4: 175-177.

431. Book review: I. Rosenfield. *The Invention of Memory: A New View of the Brain*. Basic Books, New York, 1987. In *Science Books & Films* 1988; 24: 77-78.

432. Book reviews: B. Aperia. *A Psychoendocrinological Study of Electroconvulsive Therapy in Major Depressive Disorder*. Thesis. Department of Psychiatry, Karolinska Institute, St Gyran's Hospital, Stockholm, Sweden, 1985. P. Silfverskiöld. *Depression and Mania: Clinical and Neurophysiological Aspects and Effects of ECT*. Thesis. Department of Psychiatry, University of Lund, Lund, Sweden, 1987. In *Convulsive Ther* 1988; 4: 177-179.

433. Book review: *Current Approaches: ECT*. J. Malkien, S. Brandon. Duphar Laboratories, UK, 1988. In *Convulsive Ther* 1988; 4: 335-336.

434. Book review: R.E. Hales, S.C. Yudofsky (eds.): *Textbook of Neuropsychiatry*. APA Press, Washington DC, 1987. In *Neuropsychiatry, Neuropsychol Behav Neurology* 1987; 1: 153-155.

435. Book review: P.H. Wender. *The Hyperactive Child, Adolescent and Adult: Attention Deficit Disorder Through the Lifespan*. Oxford University Press, New York, 162 pp., 1987. In *Science Books & Films*, 1988; 23: 244.

436. Videotape Review: Healthcare Information Network, Princeton NJ. *Electroconvulsive Therapy: A New Age, A New Understanding*. Series: *Mind and Body*. Distributed by MECTA Corporation, Portland OR, 1987. In *Convulsive Ther* 1988; 4: 180.

1989

437. Convulsive therapy: A reappraisal. In J.G. Howells (ed.): *Modern perspectives in the Psychiatry of Affective Disorders*. Brunner/Mazel Inc., New York, 1989; 22: 393-410.

438. Electroconvulsive therapy: The forgotten option in the treatment of therapy resistant depression. In I. Extein (ed.): *Treatment of Tricyclic Resistant Depression*. APA Press, Washington DC, 1989, 135-150.

439. A comparison of etomidate and methohexital anesthesia for electroconvulsive therapy. *Annals Clin Psychiatry* 1989; 1: 39-42 (with L.B. Greenberg, R. Boccio).

440. A neuroendocrine view of ECT. *Convulsive Ther* 1989; 5: 296-304 (with C.B. Nemeroff).

441. Convulsive therapy and kindling. In M. Trimble and T. Bolwig (eds.): *The Clinical Relevance of Kindling*. John Wiley & Sons, Chichester. 1989; 13: 195- 208.

442. Electroconvulsive therapy: A review. *Organorama* 1989; 26: 24-25.

443. Update on "Shock" therapy. *Health & Medical Horizons*. Macmillan Co., New York, 1989; 197-198 (commentary).

444. Recommendations for EEG and evoked-potential mapping. *Neuropsychobiology* 1989; 22: 170-176. International Pharmacology-EEG Group; (with W. Herrmann et al.).

445. Reversible and irreversible dementia. *Convulsive Ther* 1989; 5: 123-125 (editorial).
446. ECT in Parkinson disease. *The Psychiatric Times* 1989; 63: 6-7. (commentary).
447. Maintenance ECT is a continuing saga. *The Psychiatric Times* 1989; 64: 13-14. (commentary).
448. Reversible dementia and ECT. *The Psychiatric Times* 1989; 65: 23-24. (commentary).
449. Primo Levi need not have died. *The New York Times*. January 5, 1989. A20. (letter).
450. The efficacy of electroconvulsive therapy in therapy-resistant psychotic patients. *J Clin Psychopharmacol* 1989; 9: 231-232. (letter).
451. Max Hamilton. *Biol Psychiatry* 1989; 26: 218-219. (homage).
452. Maintenance ECT. In response. *Jefferson Jnl Psychiatry* 1989; 7: 71-72 (letter).
453. Videotape review: J. David. *Four Lives: A Portrait of Manic Depression*. Fanlight Productions, 1988. *Hosp & Commun Psychiatry* 1989; 40: 347-348.
454. Book review: Lader M., Lang R., Wilson G.D. *Patterns of Improvement in Depressed In-Patients*. Oxford University Press, Oxford UK, 1987, 118 pp. In *J Nerv Ment Dis* 1989; 177: 498-499.

1990

455. How does convulsive therapy work? *Neuropsychopharmacology* 1990; 3: 73-82.
456. Response to commentaries on "How does convulsive therapy work?" *Neuropsychopharmacology* 1990; 3: 97-100.
457. Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia. *Am J Medicine* 1990; 88: 443-444 (with G.L. Fricchione, L.D. Kaufman, B.L. Gruber).
458. Rat brain concentration of fluphenazine during a course of electroconvulsive shock. *Convulsive Ther* 1990; 6: 273-9 (with I. Zervas, L.B. Greenberg, R.F. Suckow, T. Cooper, L. Jandorf).
459. Electroconvulsive therapy in the elderly. *Psychiatric Annals* 1990; 20: 99-101. (with L.B. Greenberg). (review).
460. Electroconvulsive therapy. *Current Opinion in Psychiatry* 1990; 3: 58-61. (review).
461. Electroconvulsive therapy of anxiety disorders. In R. Noyes, M. Roth, G.D. Burrows (eds.): *Handbook of Anxiety IV: The Treatment of Anxiety*. Elsevier Science Publishers BV, Amsterdam, Chap 25: 511-518, 1990.
462. A trial of ECT is essential before a diagnosis of refractory depression is made. In J.D. Amsterdam (ed.): *Refractory Depression*. *Adv Neuropsychiatry Psychopharmacology* 1990; 2: 87-92. Raven Press, New York.
463. Is catatonia a primary indication for ECT? *Convulsive Ther* 1990; 6: 1-4. (editorial).

464. The 1990 APA task force report: A quiet revolution. *Convulsive Ther* 1990; 6: 75-78. (editorial).
465. ECT in modern literature. *Convulsive Ther.* 1990; 6: 191-193. (editorial).
466. Electrode placement: A clinician's guide. *Convulsive Ther.* 1990; 6: 263-265. (editorial).
467. Clozapine and electroconvulsive therapy. *Arch Gen Psychiatry* 1990; 47: 290-291. (letter).
468. Continuation ECT today. *Harvard Medical School Mental Health Letter.* (forum). 1990; 6: 8.
469. Guidelines for the long-term use of convulsive therapy. *JAMA* 1990; 264: 1174. Questions and answers.
470. Book review: L.G. Kiloh, J.S. Smith, G.F. Johnson. *Physical Treatments in Psychiatry.* Blackwell Scientific, Melbourne, 1988. In *Am J Psychiatry* 1990; 147: 1239-1240.
471. ...ibid., In *Convulsive Ther.* 1990; 6: 60-62.
472. Book review: M.R. Trimble, E.H. Reynolds (eds.): *Epilepsy, Behaviour and Cognitive Function.* John Wiley & Sons, Chichester UK, 1988. In *Am J Psychiatry* 1990; 147: 665-666.
473. Energy parameters of ECT devices need reassessment. *Psychiatric Times* 1990; 7: 23, 26. (commentary).
474. Catatonia and ECT. *Psychiatric Times* 1990; 7: 32-33. (commentary).

1991

475. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, betaendorphin and somatostatin. *Br J Psychiatry* 1991; 158: 59-63 with C.B. Nemeroff, G. Bissette G, H. Akil).
476. Catatonia: A separate category for DSM-IV? *Integrative Psychiatry* 1991; 7: 2-10 (with M.A. Taylor).
477. Impact of the anti-psychiatry movement on the revival of ECT in the U.S. *Psychiatric Clinics N.A.* 1991; 14: 793-801.
478. Electroconvulsive therapy, 1989-1990. *Current Opinion Psychiatry* 1991; 4: 73-77 (with I. Zervas).
479. The revival of ECT in America. *Bolletino di Psichiatria Biologica.* 1991; 6: 25-29.
480. What is an adequate treatment in convulsive therapy? *Acta Psychiatr Scand* 1991; 84: 424-427.
481. Electroconvulsive therapy. Review of APA Task Force report. *Wn Jrl Med* 1991; 155, 515. (review).
482. Present use of ECT. *Integrative Psychiatry* 1991; 7: 69-70. (letter).
483. Pharmacotherapy and ECT. *Convulsive Ther* 1991; 7: 77-80. (editorial).
484. A scientific society for ECT. *Convulsive Ther* 1991; 7: 155-156. (editorial).

485. ECT for refractory Parkinson's Disease. *Convulsive Ther* 1991; 7: 222-223 (with I. Zervas). (letter).
486. A historical review of electroconvulsive therapy. *Jefferson Jrl Psychiatry* 1991; 9: 97-99. (letter).
487. Steroid induced catatonia. *Br J Psychiatry* 1991; 159: 445. (letter).
488. ECT in long-term follow up of BPD. *Biol Psychiatry* 1991; 30: 1172. (letter).

1992

489. Soziale und politische Aspekte der Elektrokonvulsionstherapie in den USA: Lektionen für die deutsche Psychiatrie. Social and political aspects of ECT in the U.S.: Lessons for German psychiatry). *Biologische Psychiatrie*. Springer Verlag, Heidelberg, 1992, 88-90.
490. The use of ECT in geriatric patients. In G.S. Alexopoulos (ed.): *Clinics Geriatric Medicine* 1992; 8: 349-354, W.B. Saunders: Philadelphia (with L.B. Greenberg).
491. Electroconvulsive therapy. In E.S. Paykel (ed.): *Handbook of Affective Disorders*. 2nd ed. Churchill-Livingstone, London, 1992; 22: 359-368. (review).
492. Induced seizures ECT and memory. In D Barcia Salorio (ed.): *Trastornos de la Memoria*. Editorial MCR, Madrid. 1992; 5.1: 383-396.
493. Pharmaco-Electroencephalography: A science ignored. *Pharmacopsychiatry* 1992; 24: 183-184. (editorial).
494. Qualification for ECT. *Convulsive Ther* 1992; 8: 1-4 (with R. Abrams). (editorial).
495. ECT and public mental health services. *Convulsive Ther* 1992; 8: 87-91. (editorial).
496. Catatonia and DSM-IV. *Convulsive Ther* 1992; 8: 159-162. (editorial).
497. Book review: *Electroconvulsive therapy*. *Psychiatric Clinics N.A.* 1992; 14: 693,1020. In *Convulsive Ther* 1992; 8:54-55.
498. Book review: *ECT awaits its Lavoisier*. R. Abrams. *Electroconvulsive Therapy*, 2nd ed. Oxford University Press, New York, 340 pp., 1992. In *Convulsive Ther* 1992; 8:213-216.
499. Book review: B.N. Gangadhar (ed.). *Proceedings of the National Workshop on ECT*. NIMHANS, Bangalore, India, 264 pp., 1992. J Krzyzowski. *Leczenie Elektrowstrzasami*. Z.D. Poligraficzny, Warsaw, Poland, 215 pp., 1991. In *Convulsive Ther* 1992; 8: 216-217.
500. Failure to use ECT in a case of catatonia. *Am J Psychiatry* 1992; 149: 145. (letter).
501. The treatment of catatonia: Benzodiazepines or ECT? P.J. Rosebush, A.M. Hildebrand, M.F. Mazurek (letter). Dr. Fink replies. *Am J Psychiatry* 1992; 149: 1279-1280. (letter).
502. ECT response in catatonia. *Am J Psychiatry* 1992; 149: 581-582 (with A. Francis). (letter).

503. Why not ECT for catatonia? *Biol Psychiatry* 1992; 31: 536-537. (letter).
504. ECT and delirium in Parkinson's Disease. *Jrl Neuropsychiatry & Clin Neuroscience* 1992; 4: 231 (with I. Zervas). (letter).
505. Follow-up: Letter on review of APA Task Force report by Peter Breggin. *Readings: A Journal of Reviews and Commentary*. American Orthopsychiatry Association). 1992; 7:22-23 (with L. Eisenberg). (letter).
506. Role of Dopamine in mood disorders. *Comprehens Psychiatry* 1992; 33: 417-417 (with L. Fochtmann). (letter).
507. ECT and delirium in Parkinson's Disease. *Am J Psychiatry* 1992; 149: 1758 (with I. Zervas). (letter).
508. Missed neuroleptic malignant syndrome. *BMJ* 1992; 304: 1246. (letter).
509. Catatonia: incidence and treatment in a university hospital. *Convulsive Ther* 1992; 8: 60-61 (with I. Zervas, J. Pataki J). (abstract).

1993

510. Blood pressure, memory, and electroconvulsive therapy. *Convulsive Ther* 1993; 9: 14-22 (with I. Zervas, A. Calev, L. Jandorf).
- 511a. Caffeine pre-treatment enhances clinical efficacy and reduces cognitive effects of ECT. *Convulsive Ther* 1993; 9:95-100 (with A. Calev, G. Petrides, A. Francis, L. Fochtmann).
- 511b. Effect of ECT with caffeine pre-treatment on efficacy for depression and memory deficits. *Biol Psychiatry* 1993; 33:84A (with A. Calev).
512. Who should get ECT? In C.E. Coffey (ed.): *The Clinical Science of Electroconvulsive Therapy*. 1993; 1: 3-16. APA Press, Washington, DC.
513. Catatonia: A treatable disorder, occasionally recognized. *Directions in Psychiatry*. 1993; 13(3): 1-8 (with G. Bush, A. Francis).
514. Die Geschichte der EKT in den USA in den letzten Jahrzehnten. (Recent history of electroconvulsive therapy in the U.S.) *Nervenarzt*. 1993; 64: 689-95.
515. Subjective symptoms in depression and during the course of electroconvulsive therapy. *Neuropsychiatry, Neuropsychol Behav Neurol*. 1993; 6: 187-92 (with N. Tubi, A. Calev, D. Nigal, B. Shapira, H.L. Pass, L. Jandorf, B. Lerer).
516. Post-ECT delirium. *Convulsive Ther* 1993; 9: 326-330. (review).
517. Reversible dementia and affective disorder: The Rip van Winkle Syndrome. *Convulsive Ther* 1993; 9: 209-16 (with L. Bright-Long). (case report).
518. Combining drugs and electroconvulsive therapy: Safe and/or effective? *J. Clin. Psychopharmacology* 1993; 13 2): 85-86. (commentary).

519. Prolonged seizures. *Convulsive Ther* 1993; 9: 87-89. (commentary).
520. ECT in children and adolescents. *Convulsive Ther* 1993; 9: 15S-7. (commentary).
- 521a. The next challenge: The mode of action of ECT. *Convulsive Ther* 1993; 9: 192-7. (annotation).
- 521b. The mode of action of ECT. *Psychopharmacol. Bull.* 1994; 30: 309-12, 1994.
522. ECT and drugs: Concurrent administration. *Convulsive Ther* 1993; 9: 237-40. (with C.H. Kellner). (commentary)
523. Commentary on J.B. Welch: Topographic brain mapping: Applications and pitfalls. *Integrative Psychiatry* 1993; 9: 67-8.
524. EEG and behavior: Association or dissociation in man? *Integrative Psychiatry* 1993; 9: 108-123. (hypothesis).
525. Catatonia and psychotic delusional depression, distinct syndromes in DSM-IV. *Am. J. Psychiatry* 1993; 150: 1130-1. (letter).
526. Using MEDLINE to solve clinical problems. *JAMA* 1993; 270: 2053 (letter).
527. Book review: "Round up a new set of suspects..." Review of M.K. O'Connor, T.A. Rummans (eds): *Updating ECT. Psychiatric Annals*, 1993; 23:1-47. In *Convulsive Ther* 1993; 9: 141-2.
528. Book review: *Psychiatry: The next phase*. Review of M. Taylor: *The Neuropsychiatric Guide to Modern Everyday Psychiatry*. The Free Press, New York, 530 pp., 1993. In *Convulsive Ther.* 1993; 9: 143-5.
- 529a. Question the Experts: Blood levels of nortriptyline. *J Clin Psychopharmacology* 1993; 13: 296.
- 529b. Reply to "Question the Experts." *J Clin. Psychopharmacology* 1993; 13: 359.
530. Book review: *Psychiatry's frog or prince? Electroconvulsive Therapy*. Richard Abrams, Oxford University Press, 1992. In *BJP Review of Books* 6:18-19, July, 1993.
531. Book review: *Electroconvulsive Therapy*. Richard Abrams, Oxford University Press, 1992, 2nd ed. In *Am. J. Psychiatry* 1993; 150:1747-8.
532. Book review: *Neuropsychological Perspectives on Emotion*. F.N. Watts. Hillsdale, NJ: Lawrence Erlbaum. In *Science Books & Films* 1993; 29:261.
533. Book review: *Motor Disorders in Psychiatry*. D. Rogers, Wiley & Sons, Chichester UK, 1992. In *Neuropsychiatry, Neuropsychol Behav Neurol* 1993; 6: 267-8.
- 534a. Catatonia: A rating scale and prospective study utilizing lorazepam and ECT. *Amer Col Neuropsychopharmacology Abstracts*, pg 88, December 1993 (with G. Bush, A. Francis, G. Petrides, F. Dowling).
- 534b. What is catatonia? *The Harvard Mental Health Letter* 1995; 11: 8 (with G. Bush, G. Petrides). (commentary).

1994

- 535a. Continuation ECT for relapse prevention in depression. *Convulsive Ther* 1994; 10: 77 (with G. Petrides, D. Dhossche). (abstract).
- 535b. A prospective study of continuation ECT. *Biol. Psychiatry* 1994; 35: 652-3 (with G. Petrides , D. Dhossche, A. Francis). (abstract).
- 535c. Continuation ECT: Relapse prevention in affective disorders. *Convulsive Ther* 1994; 10: 189-94 (with G. Petrides G., D. Dhossche, A. Francis).
536. Indications for the use of ECT. *Psychopharmacol. Bull.* 1994; 30: 269-80.
- 537a. Combining electroconvulsive therapy and drugs: A review of safety and efficacy. *CNS Drugs* 1994; 1: 370-376. (review).
- 537b. ECT and psychoactive drugs combined. *ASCP Progress Notes Newsletter* 1994; (52): 3. (review).
538. Optimizing ECT. *L'Encephale* 1994; 20: 297-302. (review).
- 539a. ECT in adolescents. *The Harvard Mental Health Letter* 1994; 10: 8. (commentary).
- 539b. ECT in adolescents. *Psychiatric Times* 1994; 12: 18-19,1995. (commentary).
- 540a. Catatonia in DSM-IV. *Biological Psychiatry* 1994; 36: 431-3. (commentary).
- 540b. DSM-IV and catatonia. *Psychiatric Times* 1994; 11: 35. (commentary).
541. Public perceptions of ECT. *Jefferson Jrl. Psychiatry* 1994; 12: 83-86. (letter).
542. Administrative problems limiting electroconvulsive therapy. *Br. J. Psychiatry* 1994; 164: 850-1. (letter).
543. Diazepam or lorazepam for prolonged seizures? *Convulsive Ther* 1994; 10: 236. (letter).
544. Convalescence and ECT. *Convulsive Ther.* 1994; 10: 301-3. (letter).
545. Book review: *The Clinical Science of Electroconvulsive Therapy*. C.E. Coffey (ed.), American Psychiatric Press, Washington DC, 259 pp., 1993. In *The Psychiatric Times*, Feb. 1994, pg. 25.
546. Book review: *Drugs and Disease*. J. L. Harris. Twenty-First Century Books, New York, 1993. In *Science Books* 1994; 30: 82.
547. Book review: *Cannabis, Politically Incorrect. Marihuana, The Forbidden Medicine*. L. Grinspoon, J.B. Bakalar. Yale University Press, New Haven, CT, 1993. In *Am. J. Psychiatry* 1994; 151: 1091.
548. The half-age stimulation strategy for bilateral ECT. *Biol. Psychiatry* 1994; 35: 653 (with G. Petrides). (abstract).
549. Alternative stimulation strategies for bilateral ECT. *Convulsive Ther* 1994; 10: 77 (with G. Petrides).

(abstract).

1995

550. Convulsive therapy in delusional disorders. *Psychiatric Clinics North America* 1995; 18 (2): 393-406. (review).

551. ECT and non-memory cognition: A review. *Br. J. Clin Psychology* 1995; 34: 505-15 (with A. Calev, E.A. Gaudino, N.K. Squires, I.M. Zervas).

552. Recognizing NMS as a type of catatonia. *Neuropsychiatry Neuropsychol Behav Neurol.* 1995; 8: 75-6. (commentary).

553. Treat NMS as catatonia. *Psychiatric Times* 1995; 12 (3): 34. (commentary).

554. ECT in mania: A rediscovered use. *Psychiatric Times* 1995; 12 (6): 16.

555. ECT and schizophrenia. *Psychiatric Times* 1995; 12 (10): 30.

556. Milton Greenblatt: a remembrance. *Convulsive Ther* 1995; 11: 151-3 (with F. Frankel).

557. Convalescence and ECT: Comment on Letter by Dr. Brackin. *Convulsive Ther* 1995; 11: 220-21. (letter).

558. ECT and young minds. *Lancet* 1995; 345: 519. (letter).

559. NMS and catatonia: Reply to Raja and Miti. *Neuropsychiatry Neuropsychol Behav Neurol* 1995; 8: 230-1. (letter).

560. "An ethical dilemma" *Psychiatric Bulletin* 1995; 19: 650-1 (with D.F. Klein). (letter).

561. ECT and pre-pubertal children. *J Am Acad Child Adolesc Psychiatry* 1995; 34: 1256-7 (with G.A. Carlson). (letter).

562. Book review: F.E. Bloom, O.J. Kupfer (eds.): *Psychopharmacology: The Fourth Generation of Progress*. New York, Raven Press, 1995, 2002 pp. In *Neuropsychiatry, Neuropsychol. & Behav Neurol.* (84): 303-4.

563. Book review: Asaad, Ghazi: *Understanding mental disorders due to medical conditions or substance abuse: What every therapist should know*. Brunner Maazel, NY, 1995. In *Science Books & Films* 31 (5): 134-5. (book review).

564. Book review: J. Morrison: *DSM-IV Made Easy: The Clinician's Guide to Diagnosis*. Guilford Press, NY, 1995. In *Science Books & Films* 31 (8): 233.

1996

565. Atrial fibrillation, anticoagulation, and electroconvulsive therapy. *Convulsive Ther.* 1996; 12: 91-98 (with G. Petrides).

566. Ambulatory electroconvulsive therapy. Task force report of the association for convulsive therapy. *Convulsive Ther.* 1996; 12: 42-55 (with R. Abrams, S. Bailine, R. Jaffe).
567. Convulsive therapy for schizophrenia? *Schizophrenia Bull.* 1996; 221: 27-39 (with H.A. Sackeim).
568. Catatonia: I: rating scale and standardized examination (with G. Bush, G. Petrides, F. Dowling, A. Francis). *Acta Psychiatr. Scand* 1996; 93 (2): 129-36.
569. Catatonia: II. Treatment with lorazepam and electroconvulsive therapy (with G. Bush, G. Petrides, F. Dowling, A. Francis). *Acta Psychiatr. Scand* 1996; 93 (2):137-43.
570. Catatonia. In T.A. Widiger, A.J. Frances, H.A. Pincus et al. (eds.): *DSM-IV Sourcebook*, 1996; vol 2:181-192.
571. The “half-age” stimulation strategy for ECT dosing. *Convulsive Ther* 1996; 12: 138-146 (with G. Petrides).
572. Toxic serotonin syndrome or neuroleptic malignant syndrome? *Pharmacopsychiatry* 1996; 29: 159-161. (case report).
573. A second quiet revolution: Ambulatory ECT. *Convulsive Ther* 1996; 12: 1-2 (with C.H. Kellner). (editorial).
574. Seizure adequacy: Does EEG hold the key? *Convulsive Ther.* 1996; 12: 203-206 (with C.H. Kellner). (editorial).
575. Neuroleptic malignant syndrome and catatonia: One entity or two? *Biol Psychiatry* 1996; 39: 1-4. (editorial).
576. Ambulatory ECT and managed care. *The Psychiatric Times* 1996; 13: 42.
577. Response to “Neuroleptic malignant-like syndrome due to cyclobenzaprine?” *J Clin Psychopharmacol.* 1996; 16: 97-9. (letter).
578. “Abnormal EEG effects of Clozapine.” *J Neuropsych Clin Neuroscience* 1996; 8: 114-115. (letter).
579. Algorithm accuracy. Comment on the International Psychopharmacology Algorithm Project. *Psychiatric Times* 1996; 13(8): 5. (letter).
580. Treating the syndrome before the complications. *Am J Psychiatry* 1996; 153: 1371 (with A. Francis). (letter).
581. Choosing a dosing strategy for electrical stimulation in ECT. *J Clin Psychiatry* 1996; 57: 487. (with G. Petrides). (letter).
582. ‘Catatonic schizophrenia’ is not ‘schizophrenia.’ *Schizophrenia Res* 1996; 18: 118. (abstract).
583. Book review: C. P. Freeman (ed.): *The ECT Handbook*. Royal College of Psychiatrists, London, 153 pp., 1995. In *Convulsive Ther* 1996; 12: 127-130.

584. Book review: Bergsholm P.: *Electroconvulsive Therapy: Issues related to narcosis, physiology, radiological anatomy, electrode placement, and endocrinology*. Forde/Bergen, University of Bergen, 1995. In *Convulsive Ther* 1996; 12: 131-132.

1997

585. Catatonia. In M. Trimble, J. Cummings (eds.): *Contemporary Behavioural Neurology*. 1997; Chapter 16; pages 289-309. Butterworth/Heinemann, Oxford, UK.

586a. Prejudice against ECT: Competition with psychological philosophies as a contribution to its stigma. *Convulsive Ther* 1997; 13: 253-265.

586b. Response to Zigmund M. Lebensohn. *Convulsive Ther* 1997; 13: 268.

586c. Electroshock and psychoanalysis: schism in American psychiatry. *Convulsive Ther* 1997; 13: 51-52.

587. Recognition and treatment of the catatonic syndrome. *Jrl Intensive Care Med*. 1997; 12: 135-147 (with G. Fricchione, G. Bush G, M. Fozdar, A. Francis). (review).

588. Neuroleptic malignant syndrome: Identification and treatment. *Essential Psychopharmacology*. 1997; 2: 209-16. (review and commentary).

589. Energy dosing in ECT: Threshold stimulation or formula? *Convulsive Ther*. 1997; 13: 4-6. (debate with Richard Weiner).

590. Clinical common sense versus theoretical correctness. Reply to Harold A. Sackeim. *Convulsive Ther*. 1997; 13: 41-43 (with G. Petrides).

591. The decision to use ECT: For Whom? When? In A.J. Rush (ed.): *Mood Disorders: Systematic Medication Management. Modern Probl. Pharmacopsychiatry*. 1997; 25: 203-214. Karger, Basel, Switzerland.

592. Electroconvulsive therapy in affective disorders: Efficacy and mode of action. In A. Honig, H.M. van Praag (eds.): *Depression: Neurobiological, Psychopathological and Therapeutic Advances*. 1997; Chapter 23, pages 397-412. John Wiley & Sons, Ltd. Sussex, England.

593. What is the role of ECT in the treatment of mania? *The Harvard Mental Health Letter* 1997; 18: 8.

594. Cognitive screening instruments in neuropsychiatry: A report of the committee on research of the American Neuropsychiatric Association. *J Neuropsychiatry Clin Neurosci*. 1997; 9:189-97 (with P.F. Malloy, J.L. Cummings, C.E. Coffey, J. Duffy, E.C. Lauterbach, M. Lovel, D. Royall, S. Salloway).

595. Lethal catatonia, neuroleptic malignant syndrome, and catatonia: A spectrum of disorders. Reply. *J Clin Psychopharmacol*. 1997; 17: 237. (letter).

596. The importance of a differentiated psychopathology of catatonia. *Acta Psychiatr. Scand*. 1997; 95: 358-9 (with G. Petrides, G. Bush, A. Francis). (letter).

597. ECT Update. *Psychiatric Times*. 1997; 14: 39-41. (review and lesson).

598. Catatonia and NMS: Recognition and treatment. *The Psychiatric Times*. 1997; 14: 42-49. (review and lesson).

599. A.E. Bennett and curare. *Convulsive Ther* 1997; 13: 92. (commentary).

600. Book review: Squire L. *A History of Neuroscience in Autobiography*. Washington DC, Society for Neuroscience. vol 1, 1996. In *Science Books & Films* 1997; 33: 137.

601. Book review: *New histories of psychiatry: Somatic and dynamic views contrasted*. Shorter E. *A History of Psychiatry. From the Era of the Asylum to the Age of Prozac*. John Wiley & Sons, N.Y. 1997; Stone MH. *Healing the Mind. A History of Psychiatry from Antiquity to the Present*. W.W. Norton & Co., N.Y. 1997. In *Convulsive Ther* 1997; 13: 280-1.

1998

602. Electroconvulsive therapy and managed care. *Am Jrl Managed Care*. 1998; 4: 107-112 (with S. Bailine).

603. ECT and managed care. *Journal Watch: Psychiatry*. 1998; 4: 76 (73).

604. ECT in older patients: Benefits and risks. *Psychiatric Times* 1998; 15(2): 68-71. (lesson).

605. ECT certification. *J ECT* 1998; 14: 1-4 (with C.H. Kellner). (editorial).

606. ECT and clozapine in schizophrenia. *J ECT* 1998; 14: 223-6. (editorial).

607. ECT in mania: An ignored and effective treatment option. *Jrl Bipolar Disorders* 1998; 2: 19-21. (review).

608. Electroconvulsive therapy. In C.E. Coffey and R. Brumback (eds.): *Textbook of Pediatric Neuropsychiatry*, 1998; Chapter 54: 1389-1408. American Psychiatric Press, Washington, DC (with C.E. Coffey).

609. EEG monitoring in ECT: A guide to treatment efficacy. *Psychiatric Times* 1998; 15 (5): 70-2 (with R. Abrams).

610. Misguided consent for ECT. *Austral NZ Jrl Psychiatry*. 1998; 31: 209. (letter).

611. Theophylline and ECT. *J ECT* 1998; 14: 286-9 (with H.A. Sackeim). (letter).

612. Delirium following cessation of alcohol consumption. *Am J Psychiatry* 1998; 155: 1638.

613. *Pharmaco-electroencephalography: A debate in psychopharmacology*. In T. Ban, D. Healy, E. Shorter (eds.): *The Rise of Psychopharmacology and the Story of the CINP*, 1998; 151-6. Animula Publishing House, Budapest.

614. The case for formal certification in ECT. *J ECT* 1998; 14: 132. (abstract).

615. To titrate or not to titrate: A debate with a twist. *J ECT* 1998; 14: 133-4. (abstract).

616. Concurrent use of ECT and atypical antipsychotic medications. *J ECT* 1998; 14: 139-40 (with G. Petrides, A. Abaza, A. Francis). (abstract).

617. Book review: *Principles of Neuropsychopharmacology*. R.S. Feldman, J.S. Meyer, L.F. Quenzer. Sinauer: Sunderland, MA, 1997. In *Quart Rev Biol* 1998; 73: 122.

618. Video Review: *Brainstorm: The Hidden Epidemic of Depression*. Filmmakers Library, New York, 1998; 53 min. video. In *Science Books & Films* 1998; 34: 150.

1999

619a. *ELECTROSHOCK: Restoring the Mind*. Oxford University Press, New York, 157 pp. Re-issued in paperback as *Electroshock: Healing Mental Illness*, 2002.

619b. *Eletrochoque. Restaurando a Mente*. Portugese translation by Dra. Andrea Favano. Sao Paulo Brazil: Editora Roca Ltda, 2003.

620. www.electroshock.org. (website, July 1999).

621a. Electroconvulsive therapy and mental retardation. *J ECT* 1999; 15: 140-9 (with M. Thuppal).

621b. Electroconvulsive therapy and mental retardation. *J ECT* 1998; 14: 142 (with M. Thuppal). (abstract).

622. Delirious mania. *Bipolar Disorders* 1999; 1: 54-60.

623. ECT in delirious states. *J ECT* 1999; 15: 175-77. (editorial).

624. *Convulsive therapy*. In G. Adelman, B.H. Smith (eds.): *Elsevier's Encyclopedia of Neuroscience. Elsevier Science*. B.V., New York and Amsterdam, 466-468, 1999.

625. Convulsive Therapy. In H. Freeman (ed.): *A Century of Psychiatry*, Mosby-Wolfe, London, 1999; I: 96-99; II: 229-32.

626. Ladislav J. Meduna. Images in psychiatry. *Am J Psychiatry* 1999; 156: 1807.

627. Intractable seizures, status epilepticus, and ECT. *J ECT* 1999; 15: 282-4 (with C. Kellner, H.A. Sackeim). (letter).

628. Pediatric ECT. *Psychiatric Times* 1999; 169: 63-5 (with C. Foley).

629. Neuroleptic malignant syndrome: Recognition and treatment. *Psychiatric Times* 1999; 16 (8): 6. (commentary).

630. Book review: J.L. Beyer, Weiner R.D., Glenn M.D.: *Electroconvulsive Therapy: A Programmed Text*. American Psychiatric Press, Inc., Washington DC, 1998, *Am J. Psychiatry* 1999; 156: 333.

2000

631. Electroshock revisited. *Amer Scientist* 2000; 88 (2): 162-167.
632. Catatonia. In C. Andrade (ed.): *Advances in Psychiatry*. New Delhi, Oxford University Press. Chapter 2, pp. 26-44, 2000 (with G. Petrides).
633. A clinician-researcher and ECDEU: 1959-1980. In T. Ban, D. Healy, E. Shorter (eds.): *The Triumph of Psychopharmacology and the Story of the CINP*. Budapest, Animula, 2000, 82-96, 2000.
634. Can delirium relieve psychosis? *Comprehens Psychiatry* 2000; 41: 450-453 (with C. Malur, A. Francis).
635. ECT has proved effective in treating depression. *Nature* 2000; 405: 826. (letter).
636. The interaction of delirium and seizures. In P.T. Trzepacz (ed.) *Seminars in Clinical Neuropsychiatry* 2000; 52: 31-35.
637. Educational resources for electro-convulsive therapy. *Arch Indian Psychiatry* 2000; 6: 6-9.
- 638a. ECT in the management of delirium, NMS, and catatonia. *Essential Psychopharmacology* 2000; 3: 1-16.
- 638b. ECT in the management of delirium, NMS, and catatonia. *Directions in Psychiatry* 2000; 220: 367-376. (lesson).
639. Herman C.B. Denber. *Neuropsychopharmacology* 2000; 23:474-475. (obituary).
640. Undiagnosed Stupor: A treatable syndrome of catatonia? *ASCP Progress Notes* 2000; 10: 1,4,7.
641. Fixed high dose right unilateral ECT. (commentary). *Evidence-Based Mental Health* 2000; 3: 114-115.
642. Controversies in the diagnosis and treatment of manic-depressive illness. *World Jrl Biological Psychiatry* 2000; 1: 219. (letter).
643. NMS best treated as catatonia. *Psychiatric Times* 2000; 17 (11): 28-29. (commentary).
644. Book review: *The Science of Happiness: Unlocking the Mysteries of Mood*. Stephen Braun. NY, Wiley, 2000. In *Science Books & Films*, 2000:36 (5): 212.
645. A neuroendocrine view of convulsive therapy. *Neuropsychopharmacology* 2000; 23: S91. (abstract).

2001

646. Convulsive therapy after 65 years. *J Affective Dis.* 2001; 63: 1-15.
647. ECT remission rates in psychotic versus non-psychotic depressed patients: A report from CORE. *J ECT* 2001; 17: 244-253 (with G. Petrides, M.M. Husain, R. Knapp, A.J. Rush, M. Mueller, T.A. Rummans, K.M. O'Connor, K.G. Rasmussen, H.J. Bernstein, M. Biggs, S.H. Bailine, C.H. Kellner).
648. The influence of age on the response of patients with major depression to electroconvulsive therapy. *Am J Geriatr Psychiatry* 2001; 9: 382-390 (with K.M. O'Connor, R. Knapp, M.M. Husain, T.A. Rummans, G. Petrides, G. Smith, M. Mueller, K. Snyder, H. Bernstein, A.J. Rush, C. Kellner).
649. ECT has much to offer our patients: It should not be ignored. *World Jrl Biological Psychiatry* 2001; 2: 1-8.
650. Electroconvulsive therapy in medication-resistant depression. In Jay Amsterdam, Mady Hornig-Rohan, and Andrew Nierenberg (eds.): *Treatment resistant mood disorders*. 2001; 11: 223-238. Cambridge University Press, Cambridge UK.
651. Convulsive therapy in the 21st Century. In M.G. Gelder, J.J. Lopez-Ibor and N.C. Andreasen (eds.): *New Oxford Textbook of Psychiatry*, Oxford University Press, London. Chap 6.2.9.1; pp. 1342-1352.
652. The many varieties of catatonia. *European Arch Psychiatry Clin Neurosci* 2001; 251: Suppl 1: 8-13 (with M.A. Taylor).
653. Catatonia: Syndrome or schizophrenia subtype? Recognition and treatment. *J Neural Transmission* 2001; 108: 637-644.
654. The broad clinical activity of ECT should not be ignored. *J ECT* 2001; 17: 233-235. (editorial).
655. New research improves ECT outcomes. *Psychiatric Times* 2001; 18: 21. (review).
656. Electrode placement and electroconvulsive therapy: A search for the chimera. *Arch Gen Psychiatry*. 2001; 58: 607-608. (with S. Bailine, G. Petrides). (letter).
657. Modal ECT is effective: Response to Letter by Sackeim et al. *J ECT* 2001; 17: 222-225. (letter).
658. Treating neuroleptic malignant syndrome as catatonia. *J Clin Psychopharmacol.* 2001; 21: 120-121. (letter).
659. Treating manic stupor. *Indian J Psychiatry* 2001; 433: 286-287. (letter).
- 660 Treating bipolar affective disorder. *BMJ* 2001; 322: 365. (letter).
661. Book review: *A Century of Psychiatry*. Hugh Freeman. London, Mosby-Wolfe Medical Communications. In *Neuropsychiatry, Neuropsychology Behavioral Neurology* 2001; 14: 77.

2002

662. The efficacy of ECT and "Treatment Resistance." *J ECT* 2002; 18: 1-2.

663. Move On! Commentary on R. Abrams: stimulus titration and EC T dosing. *J ECT* 2002; 18: 11-12.
664. Catatonia and ECT. Reconsidering Meduna's hypothesis of a biological antagonism between dementia praecox and epilepsy. *World Jrl Biol Psychiatry* 2002; 3: 105-108.
665. The 21st century clinical evaluation of psychoactive drugs. In T. Ban, D. Healy, E. Shorter (eds.): *From Psychopharmacology to Neuropsychopharmacology in the 1980s and the Story of CINP as told in Autobiography*. Budapest: Animula Publishing, 2002; 21-26.
666. ECT: an effective, but ignored, treatment of psychosis. In B. Green (ed.): *Focus on Antipsychotics*. London: Librapharm/Petroc Press, 2002, 3: 10-17.
667. Equivalency of rTMS and ECT unproven. *Biol Psychiatry* 2002; 52: 1032-1033 (with C.H. Kellner, M. Husain, G. Petrides, T. Rummans). (letter).
668. Electrotherapeutics. *J ECT* 2002; 18: 114-115.
669. Catatonia and NMS. (Grand Rounds Response) *Psychiatric Bull.* 2002; 26: 393. (with M.A. Taylor). (letter).
670. ECT in neurological disorders. *Psychiatric Times* 2002; 19 (9): 28-29.
671. Catatonia in adolescents and children. *Psychiatric Times* 2002; 19 (9): 28-29.
672. Book review: American Psychiatric Association. *The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging*. 2nd ed. *Psychiatric Services*. 2002; 53: 1040-1041.
673. Book review: *Rage Against Electroshock*. Kneeland TW, Warren CAB. *Pushbutton Psychiatry*. Westport CT: Praeger, 2002. *J ECT* 2002; 18: 112-113.
674. Book review. *Electricity in Medicine: Ugo Cerletti's Contribution. Electric Bodies: Episodes in the History of Medical Electricity*. Paola Bertucci, Giuliano Pancaldi (eds.). Bologna, Italy: Universita di Bologna, 2001. *J ECT* 2002; 18:165-166.

2003

- 675a. *Catatonia. A Clinician's Guide to Diagnosis and Treatment*. Cambridge UK: Cambridge University Press (with M.A. Taylor).
- 675b. *Catatonia. Guía clinica para el diagnóstico y el tratamiento*. Translated into Spanish by Beatriz M. Ruiz and Miguel B. Arroyo. Barcelona: Masson, 2005.
- 675c. ...ibid., Translated into Japanese by Kazumasa Suzuki. Tokyo: Seiwa Shoten, 2007.
676. Catatonia in psychiatric classification: A home of its own. *Am J Psychiatry* 2003; 160: 1233-1241 (with M.A. Taylor).
677. A Beautiful Mind and insulin coma: social constraints on psychiatric diagnosis and treatment. *Harvard Review of Psychiatry* 2003; 11: 284-290.

678. A Gilles de la Tourette form of catatonia: Response to ECT. *J ECT* 2003; 19(2): 115-117. (with H. Trivedi, A. Mendelowitz).
679. ECT Update: Recognizing and treating psychotic depression. *J Clin Psychiatry* 2003; 64: 232-234.
680. Therapy-Resistant Depression: When to consider ECT. Algorithm seeks respect for neglected therapy. *Current Psychiatry* 2003; 2: 49-54.
681. Commentary on “Successful use of ECT as the sole modality of treatment in a case of motility psychosis”: The classification of catatonia. *J ECT* 191: 48- 49, March 2003 (with M.A. Taylor).
682. Electroshock 2003. *Masterminds Indian Psychiatric Society* (Jan) 2003, 3-4.
683. Letter from India: Conflicts in the use of ECT. *Psychiatric Times* 2003 (Mar); 20: 10.
684. Book review. *A classic text updated*. Abrams R: *Electroconvulsive Therapy*, New York: Oxford University Press. *J ECT* 2003; 19:123-124. *ibid.* *Psychiatric Times* 2003 (Jun); 20: 25.
685. Book review. D. Healy. *The Creation of Psychopharmacology*. Cambridge MA: Harvard University Press, 2002. *Psychiatric Times* 2003; 220: 29.
686. Book review. G. Parker, D. Straton, K. Wilhelm, P. Mitchell; M-P. Austin, K. Eyers, D. Hadzi-Pavlovic. *Dealing with Depression: A Commonsense Guide to Mood Disorders*. New South Wales: Crows Nest, 2002. *Am J Psychiatry* 2003; 160:1365-1366.
687. Book review: K. Hugdahl, R.J. Davidson. *The Asymmetrical Brain*. Cambridge MA: MIT Press, 2003. *Science Books & Films* 2003; 9: 160.

2004

- 688a. *Ethics of Electroconvulsive Therapy*. New York: Brunner-Routledge (with J.O. Ottosson).
- 688b. ...*ibid.*, Translated into Japanese by Mitsuru Nakamura. Tokyo: Seiwa Shoten, 2006.
689. Pharmaco-Electroencephalography: A Selective History of the Study of Brain Responses to Psychoactive Drugs. In *History of CINP*, vol IV. Edited by T. Ban, E. Shorter, D. Healy. pp. 661-672.
690. Speed of Response and Remission in Major Depressive Disorder with Acute ECT: A Consortium for Research in ECT (CORE) Report (with M.M. Husain, A.J. Rush, R. Knapp, G. Petrides, T. Rummans, M.M. Biggs, K.M. O’Connor, K. Rasmussen, M. Litle, W. Zhao, H.J. Bernstein, G. Smith, M. Mueller, S.M. McClintock, S.H. Bailine, C.H. Kellner). *J Clin Psychiatry* 2004; 65: 485-491.
691. Efficacy of ECT in catatonia. In S.Caroff, S.Mann, A. Francis, G Fricchione (eds.): *Catatonia. From Psychopathology to Neurobiology*. Washington DC: American Psychiatric Press. 13: 151-160 (with G. Petrides, C. Malur).
692. Induced seizures as psychiatric therapy: Ladislav Meduna’s contributions in modern neuroscience. *J ECT* 2004; 20: 133-136. (commentary).
693. Response to T.E. Schlaepfer: Learning from the history of neuroscience: Dogma and patient interests. *J*

ECT 2004; 20: 138.

694. Melancholy or Malarky? In Spitzer R.L., First M.B., Gibbon M., Williams J.B.W. (eds.): *Treatment companion to the DSM-IV-TR casebook*. Washington DC: American Psychiatric Publishing, 2004; 112-119.

695. Response to critique: classification of catatonia. *Am J Psychiatry* 2004; 161: 1136 (with M.A. Taylor). (letter).

696. Response. Catatonia in psychiatric classification. *Am J Psychiatry* 2004; 161: 2328.

697. Non-convulsive status epilepticus and electroconvulsive therapy. *J ECT* 2004; 20: 131-2. (letter).

698. Treat TSS and NMS as malignant catatonia. *BMJ* (rapid responses) 2004; 329: 1333-1335.

699. Convulsive therapy electroshock (ECT). In G. Adelman, B.H. Smith (eds.): *Encyclopedia of Neuroscience*, 3rd ed. Amsterdam: Elsevier B.V., 2004.

700. Insulin coma therapy (ICT). *Encyclopedia of Neuroscience*. In G. Adelman, B.H. Smith (eds.): *Encyclopedia of Neuroscience*, 3rd edition. Amsterdam: Elsevier B.V., 2004.

701. About Meduna's pioneer activity. *Neuropsychopharmacol Hung* 2004; 6: 39. (letter).

702. ECT: Serendipity or logical outcome? *Psychiatric Times* 2004; 211: 21-22.

703. A new appreciation of ECT. *Psychiatric Times* 2004; 214: 32-35.

704. ECT at 70: What have we learned? *Psychiatric Times* 2004; 21(8): 13-14.

705. Book review. The Mount Everest Challenge. Lisanby S.H. (ed.): *Brain Stimulation in Psychiatry*. Washington DC: American Psychiatric Publishing Inc. *Am J Psychiatry*. 2004 (161): 2149-2150.

706. Book review. Schroeder B.E.: *Ecstasy*. Philadelphia: Chelsea House, 2003. *Science Books and Films* 2004 (May-June); 127.

2005

707. *Catatonia. Guia clinica para el diagnóstico y el tratamiento*. (Spanish translation). Barcelona: Masson Elsevier.

708. Psychobiology of Electroshock. In J. Licinio (ed.): *Biology of Depression*. Weinheim, Germany: Wiley-VCH, 2004. Chap 7: 211-221.

709. Relief of expressed suicidal intent by ECT: A Consortium for Research in ECT Study. *Am J Psychiatry* 2005;162: 977-982 (with C.H. Kellner, R. Knapp, G. Petrides, M.M. Husain, T. Rummans, M. Mueller, H. Bernstein, K. Rasmussen, K. O'Connor, G. Smith, A.J. Rush, M. Biggs, S. McClintock, S.H. Bailine, C. Malur).

710. Should the dexamethasone suppression test be resurrected? *Acta Psychiatrica Scandinavica* 2005; 112:

245-9. (commentary).

711. Is the practice of ECT ethical? *World Jnl Biological Psychiatry* 2005; 6 (Supplement 2): 38-43.

712. The “treatment resistant” label in bipolar disorder is a misnomer. *Psychiatric Annals* 2005; 35: 965-8. (review).

713. Predicting the response to ECT. *J ECT* 2005; 21(3): 137-8. (editorial). (with V. McCall).

714. William Karlner: practitioner, experimentalist, and teacher. Obituary. *J ECT* 2005; 21: 201-2.

715. Suicide risk reduced. *Psychiatric Times* 2005; 222: 94-95.

716. The bean-counters view of ECT. *Psychiatric Times* 22; 10: 54.

717. Continuation ECT Today: What we know and what we need to know. *Psychiatric Times* 2005; 2214: 76-77.

718. Use of pharmacologic coma for adult status epilepticus. *Epilepsy & Behavior*. 2005; 6: 292 (letter). (with D. Anshel).

719. Cheap shot at ECT. *Lancet* 2005; 365: 937 (with C. Kellner, V. McCall). (letter).

720. Book review. Kelleher, C.A.: *Brain Trust*. New York: Paraview Pocket Books, 2004. *Science Books and Films* 2005; 41:105.

721. Book reviews. Scull A. *Madhouse: A Tragic Tale of Megalomania and Modern Medicine*. New Haven: Yale University Press, 2005; J. El-Hai. *The Lobotomist: A Maverick Medical Genius and his Tragic Quest to Rid the World of Mental Illness*. New York: Wiley, 2005. *J ECT* 2005; 21: 191-3.

722. Book review. A. Scull: *Madhouse: A Tragic Tale of Megalomania and Modern Medicine*. New Haven: Yale University Press, 2005. *Science Books and Films* 2005; 41: 251.

2006

723. *Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Disorders*. Cambridge UK: Cambridge University Press, 2006 (with M.A. Taylor).

724. Catatonia in autistic spectrum disorders: A medical treatment algorithm. In D. Dhosshe, L. Wing, M. Ohta, K-J Neumarker (eds.): *Catatonia in Autism Spectrum Disorders*. Amsterdam: Elsevier/Academic Press. *Int Rev Neurobiology* 2006; 72:233-244 (with M.A. Taylor, N. Ghaziuddin).

725. Patterns of Psychotropic Medication Use Among Severely Depressed Patients Referred for Electroconvulsive Therapy: Data from the Consortium for Research on ECT. *J ECT* 2006; 22: 116-123 (with K.G. Rasmussen, M. Mueller, C.H. Kellner, R.G. Knapp, G. Petrides, T.A. Rummans, M.M. Husain, K. O'Connor, J.L. Black, S. Sampson).

726. Continuation ECT versus pharmacotherapy for relapse prevention in major depression: a multi-site study from CORE. *Archives General Psychiatry*. 2006; 63: 1337-44 (with C.H. Kellner, R.G. Knapp, G. Petrides, T.A. Rummans, M.M. Husain, K. Rasmussen, M. Mueller, H.J. Bernstein, K. O'Connor, G. Smith, M. Biggs, S.H. Bailine, C. Malur, E. Yim E, S. Sampson, M Fink).
727. The case against evidence-based principles in psychiatry. *Medical Hypotheses* 2006; 67: 401-410. (with R.L. Levine).
728. Catatonia: Subtype or syndrome in DSM? *Am J Psychiatry* 2006; 163 (11): 1875-6, (with M.A. Taylor). (commentary).
729. Challenges to British ECT clinical practice. *J ECT* 2006; 22: 30-32. (commentary).
730. ECT in therapy-resistant mania: Does it have a place? *Bipolar Disorders* 2006; 8: 307-9. (commentary).
731. The DST riddle. *Psychiatric Times* 2006; 23 (2): 25-26.
732. Should the diagnosis of melancholia be revived? *Psychiatric Times* 2006; 23 (6): 78-80.
733. The Camelford hysteria: A lesson for ECT? *Psychiatric Times* 2006; 23 (11): 69-72.
734. Interseizure EEG slowing after ECT is not NCSE. *Pharmacopsychiatry* 2006; 39: 119. (letter).
735. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. *Prog NeuroPsychopharmacol Biol Psychiatry* 2006; 30:1182-1183. (with M.A. Taylor). (letter).
736. Book review: G.S. Ungvari. *Catatonia: An anthology of classical contributions*. Hong Kong: Scientific Communications Int. Ltd. 2006. *J ECT* 2006; 22: 277-8.
737. AV Review: *Healthy Brains*. Chip Taylor Communications. *Science Books & Films* 2006; 42: 138. (review).

2007

738. Resurrecting melancholia. *Acta psychiatrica scandinavica* 2007; *Supplement* 433: 14-20 (with M.A. Taylor).
739. Melancholia: Restoration in psychiatric classification recommended. *Acta Psychiatr Scand*. 2007; 115: 89-92 (with T.G. Bolwig, G. Parker, E. Shorter). (conference summary).
740. DSM melancholic features are unreliable predictors of ECT response: A CORE publication. *J ECT*. 2007; 23: 139-146 (with A.J. Rush, R. Knapp, K. Rasmussen, M. Mueller, T. Rummans, K. O'Connor, M. Husain, M. Biggs, S. Bailine, C.H. Kellner, and CORE group.)

741. Antidepressant Treatment Failure Does Not Predict Lower Remission Rates with ECT for Major Depressive Disorder. A Report from the Consortium for Research in ECT. *J Clin Psychiatry* 2007; 68: 1701-1706 (with K.G. Rasmussen, M. Mueller, R.G. Knapp, M.M. Husain, T.A. Rummans, S.M. Sampson, M.K. O'Connor, G. Petrides, C.H. Kellner).
742. Electroconvulsive therapy: Evidence and challenges. *JAMA* 2007; 298: 330-332 (with M.A. Taylor).
743. Complaints of the loss of personal memories after electroconvulsive therapy: Evidence of a somatoform disorder? *Psychosomatics* 2007; 48: 290-293.
744. Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression. *J ECT* 2007; 23: 244-250 (with K.G. Rasmussen, R.G. Knapp, M.M. Biggs, G.E. Smith, T.A. Rummans, G. Petrides, M.M. Husain, M.K. O'Connor, C.H. Kellner).
745. Belling the cat: ECT practice standards in the United States. *J ECT* 2007; 23: 3-5 (with C.H. Kellner). (commentary).
746. What we learn about continuation treatments from the collaborative ECT studies. *J ECT* 2007; 23: 215-218 (commentary).
747. Ambulatory electroconvulsive therapy. *J ECT* 2007; 23: 130. (history).
748. Antidepressant medications and other treatments of depressive disorders: A CINP Task Force report based on a review of evidence. *International Journal of Neuropsychopharmacology* 2007; 10: S1-S207. (with N. Sartorius, T.C. Baghai, D.S. Baldwin, B. Barrett, D. Brand, W. Fleischhacker, G. Goodwin, H. Grunze, M. Knapp, B.E. Leonard, J. Lieberman, Y. Nakane, R.M. Pinder, A.F. Schatzberg, J. Svestka, P. Baumann, K. Ghalib, J.C. Markowitz, F. Padberg, T. Furukawa, K.N. Fountoulakis, P. Jensen, S. Kanba, A. Riecher-Rossler).
749. Improving electroconvulsive therapy practice. *Psychiatric Times* 2007; 24 (4): 10-11.
750. Electroshock works. Why? *Psychiatric Times* 2007; 24 (6): 59-60.
751. Major studies on ECT for depression: What have we learned? *Psychiatric Times* 2007; 24 (12): 26-28.
752. Catatonia or no catatonia: Still beyond lorazepam/amobarbital. Letter and Reply. *Am J Psychiatry* 2007; 164: 525 (with M.A. Taylor).
753. The renaissance of ECT. Forward for *Electroconvulsietherapie: Aanbevelingen voor de praktijk*. P. Sienaert, J. De Fruyt, M. Dierick (eds.). Ghent: Academic Press, 2007: xv-xviii.
754. ...ibid., Book review: Dukakis K, Tye L. *SHOCK: The Healing Power of Electroconvulsive Therapy*. New York: Penguin Group, 2006. *J ECT* 2007; 23: 131-133. Commentary: Ambulatory electroconvulsive therapy (p.130).

2008

755. Restoring melancholia in the classification of mood disorders. *Jnl Affective Disorders* 2008; 105: 1-14 (with M.A. Taylor).
756. The medical evidence-based model to identify psychiatric syndromes: Return to a classical paradigm. *Acta Psychiatr Scand* 2008; 87: 81-84 (with M.A. Taylor).

757. Karoly Schaffer and his school: The birth of biological psychiatry in Hungary, 1890-1940. *Eur Psychiatry* 2008; 23(6):449-456. (with B. Baran, I. Bitter, G. Gazdag, E. Shorter).
758. Change in seizure threshold during ECT: A CORE study. *J ECT* 2008; 24: 114-116 (with G. Petrides, C.H. Kellner, M. Mueller, R. Knapp, M.M. Husain, K. Rasmussen, T.A. Rummans, K. O'Connor).
759. Outcome of ECT by race in the CORE multi-site study. *J ECT* 2008; 24: 117-121 (with M. Williams, T. Rummans, S. Sampson, R. Knapp, M. Mueller, M. Husain, K. Rasmussen, K. O'Connor, G. Smith, G. Petrides, C.H. Kellner).
- 760a. The efficacy of acute ECT in atypical depression. *J Clin Psychiatry* 2008; 69: 406-411 (with M.M. Husain, S.M. McClintock, A.J. Rush, R.G. Knapp, T.A. Rummans, K. Rasmussen, C. Claassen, G. Petrides, M.M. Biggs, M. Mueller, S. Sampson, S.H. Bailine, C.H. Kellner).
- 760b. ECT not proven for atypical depression. Response to Letter C.M. Swartz. *J Clin Psychiatry* 2008; 69: 1662-3. (with M.M. Husain, S.M. McClintock, A.J. Rush, R.G. Knapp, T.A. Rummans, K. Rasmussen, C. Claassen, G. Petrides, M.M. Biggs, M. Mueller, S. Sampson, S.H. Bailine, C.H. Kellner, S.H. Lisanby).
761. Conceptual issues in DSM-V development (commentary). *Am J Psychiatry* 2008; 165: 799. (with M.A. Taylor).
762. Continuation treatments for melancholic depression. Commentary to M. Webber: electroconvulsive therapy, *BMJ* 2008; 337: 2998 (rapid response).
763. Catatonia in autism is treatable. *Psychiatric Times* 2008; 25: 17, 20.
764. Why evidence-based medicine cannot be applied to psychiatry. *Psychiatric Times* 2008; 25: 10-12.
- 2009**
765. *Electroconvulsive Therapy: A Guide for Professionals & Their Patients*. New York: Oxford University Press, 2009.
766. Serendipity and science: A double anniversary of a treatment and a journal. *J ECT* 2009; 25: 1-2.
767. Laszlo Meduna's pilot studies with camphor induction of seizures: The first 11 patients. *J ECT* 2009; 25: 3-11 (with G. Gazdag, I. Bitter, G.S. Ungvari, B. Baran).
768. Electrotherapy of melancholia: The pioneering contributions of Benjamin Franklin and Giovanni Aldini. *J ECT* 2009; 25:15-18 (with T. Bolwig).
769. Induced therapy in man. In *Encyclopedia of Neuroscience*. 2009; 5: 117-123. Edited by Larry Squire, Floyd Bloom, Fred Gage, Nick Spitzer. Oxford: Academic Press.
770. Electroconvulsive Therapy. In *New Oxford Textbook of Psychiatry*. Edited by M.G. Gelder, J.J. Lopez-Ibor, and N.C. Andreasen. New York: Oxford University Press, 2009, vol II;6.2.10.1: 1251-1259.
771. Catatonia: A syndrome appears, disappears, and is rediscovered. *Can J Psychiatry* 2009; 54: 23-31.
772. Catatonia: Forgotten but not gone. *Arch Gen Psychiatry* 2009; 66: 1173-77 (with M.A. Taylor).

773. Catatonia in 100 words. *Br J Psychiatry* 2009; 194: 325 (with M.A. Taylor).
774. Melancholia in 100 words. *Br J Psychiatry* 2009; 194: 463 (with M.A. Taylor).
775. The electroshock riddle: effective but rejected. *Br J Psychiatry* 2009; 195: 390.
776. Biological markers for melancholic depression are effective. Comment on the WFSBP Task Force Report. *World Journal of Biological Psychiatry* 2009 (103):252-3 (with M.A. Taylor).

777. Seizure threshold in a large sample: Implications for stimulus dosing strategies in bitemporal ECT. A report from CORE (with G. Petrides, R.J. Braga, M. Mueller, R. Knapp, T. Rummans, M. Husain, K. Rasmussen, S. Bailine, C. Malur, K. O'Connor, C.H. Kellner). *J ECT* 2009; 25: 232-237.

778. Electroconvulsive therapy in the treatment of intractable status epilepticus. *Epilepsy & Behavior* 2009; 16:189-90. (letter). (with C.H. Kellner).
<http://dx.doi.org/10.1016/j.yebeh.2009.06.022>

779. DSM-V: Applying the medical model. *Psychiatric Times*. 2009, June 9: 26 (6):
<http://www.psychiatrictimes.com/display/article/10168/1420772>.

2010

780. *Endocrine Psychiatry: Solving the Riddle of Melancholia* (with E. Shorter). Oxford University Press.

781. Remembering: the forgotten neuroscience of pharmaco-EEG. *Acta Psychiatr Scand* 2010; 121: 161-73.

782. Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. *Schizophrenia Bulletin* 2009; doi: 10.1093/schbul/sbp059; 2010; 36: 314-20. (with E. Shorter, M.A. Taylor).

783. The failure of the schizophrenia concept and the argument for its replacement by hebephrenia: applying the medical model for disease recognition (with M.A. Taylor, E. Shorter, N.A. Vaidya). *Acta Psychiatr Scand* 2010; 122: 173-183.

784. Phenomenology is not enough. J. McCarthy letter (response). *Acta Psychiatr Scand*. 2011; 123: 82-83. (with M.A. Taylor, E. Shorter, N.A. Vaidya).

785. The intimate relationship between catatonia and convulsive therapy. *J ECT* 2010; 26: 243-245. (commentary).

786. Catatonia in *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. A. Francis , F. Appiani, A. Bertelsen, T.G. Bolwig, P. Braunig, S.N. Caroff, B.T. Carroll, A.E. Cavanna, D. Cohen, Cottencin O, M.J. Cuesta, J. Daniels, D. Dhossche, G.L. Fricchione, G. Gazdag, N. Ghaziuddin, D. Healy, D.F. Klein, S. Krüger, J.W.Y. Lee, S.C. Mann, M. Mazurek, W.V. McCall, W.W. McDaniel, G. Northoff, V. Peralta, Petrides G, P. Rosebush, T.A. Rummans, E. Shorter, K. Suzuki, P. Thomas, G. Vaiva, L. Wachtel). *J ECT* 2010; 26: 246-248. (letter).

787. Whither melancholia? The case for its classification as a distinct mood disorder (with G. Parker, E. Shorter, M.A. Taylor, H. Akiskal, G. Berríos, T. Bolwig, W.A. Brown, B. Carroll, D. Healy, D.F. Klein, A. Koukopolous, R. Michels, J. Paris, R.T. Rubin, R. Spitzer, C. Swartz). *Am J Psychiatry* 2010; 167: 745-47. (letter).

788. Laszlo Meduna's immigration to the United States in 1939: Correspondence with Victor Gonda (G. Gazdag, M. Fink, G. Ungvari, E. Shorter). *J ECT* 2010; 26: 79-81.
789. The human side of Laszlo Meduna. *J ECT* 26: 77-78. (commentary).
790. ECT is equally effective in unipolar and bipolar depression (with S. Bailine, R. Knapp, G. Petrides, M. Husain, K. Rasmussen, S. Sampson, M. Mueller, S. McClintock, K.G. Tobias, C.H. Kellner). *Acta Psychiatr Scand* 2010; 121: 431-436.
791. Bifrontal, bitemporal, and right unilateral electrode placement in ECT: A randomized trial (with C.H. Kellner, R. Knapp, M. Husain, K. Rasmussen, S. Sampson, M. Cullum, S. McClintock, K. Tobias, C. Martino, M. Mueller, S. Bailine, G. Petrides). *Br. J. Psychiatry* 2010; 196: 226-234.
792. A randomized controlled trial comparing the memory effects of continuation ECT versus continuation pharmacotherapy: Results from the CORE study (with G.E. Smith, K.G. Rasmussen, M. Cullum, M.D. Felmlee, G. Petrides, T.A. Rummans, M. Husain, M. Mueller, H. Bernstein, R. Knapp, M.K. O'Connor, S. Sampson, S.H. Bailine, C.H. Kellner). *J Clin Psychiatry* 2010; 71: 185-193.
793. The end of the asylum era in Central-Eastern Europe. *History of Psychiatry* 2010; 21: 501-504. (with G. Gazdag, B. Baran, Z. Rihmer).
794. ECT (Electroconvulsive Therapy) as first line treatment for psychotic depression. Letter reply to B.S. Meyers, A.J. Flynt, A.J. Rothschild et al.: The Study of Pharmacotherapy of Psychotic Depression STOP-PD. *Arch Gen Psychiatry* 2009; 66:838-47. (with C.H. Kellner, K. Tobias, G. Petrides). *Arch Gen Psychiatry*, 9 Feb 2010. (letter).
795. F.D. Zepf et al.: A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium. *Pharmacopsychiatry* 2010; 43: 157-8. (letter).
796. The perplexing history of electroconvulsive therapy in three books. *Psychiatric Times* 2010; (Oct) 27: 31 (with C.H. Kellner). (book review).
797. Book Review. *Hysteria: The Biography*. Andrew Scull. New York: Oxford University Press, 2009. SB&F April 2010.
798. Obituary: Sidney Merlis, 1925-2010. *Neuropsychopharmacology* 2010;35: 2648.

2011

799. Catatonia from its Creation to DSM5: Considerations for ICD. *Indian Jrl Psychiatry*. 2011; 53: 214-217.
800. Melancholia is a distinct identifiable mood disorder that warrants a separate category in DSM5. In: C.R. Soldatos and D.G. Dikeos (Ed): *Psychiatry and the Neurosciences: International Perspectives*. Bologna Italy: Editografica, 2011: 5-13.
801. ECT resurrected: Its successes and promises after 75 years. *Can J Psychiatry* 2011; 56:3-4 (Commentary).
802. Presidential Perspective: Defining clinical diagnoses by the medical model. In: Cottler L (Ed): *Mental Health in Public Health: The Next 100 Years*, NY: Oxford University Press, 2011: 278-281.

803. Anti-NMDA receptor encephalitis vs. pediatric catatonia. [Comment on Case Report "Anti NMDA receptor encephalitis" *Am J Psychiatry* 2011;168: 245-51]. *Am J Psychiatry* 2011; 168: 749. [Dhossche D, Fink M, Shorter E, Wachtel LE] (Letter)
804. Transcranial magnetic stimulation is not a replacement for electroconvulsive therapy in depressive mood disorders. *J ECT* 2011; 27: 3-4. (Commentary)
805. Stimulus dosing in electroconvulsive therapy. *J ECT* 2011; 27:268. [Petrides G, Braga RJ, Fink M, Mueller M, Knapp RG, Husain M, Rummans T, Bailine SH, O'Connor K, Malur C, Kellner CH.]. (Letter)
806. ECT for melancholia. *New York City Voices* 2011; 18: 16. (Letter)
807. A response to Not "Au Revoir" but "Merci Beaucoup. *J ECT* 2011; 27:339. [Bailine S, Petrides G, Kellner C, Fink M, Bolwig T, Freeman C, Greenberg R, Kramer B, Fox H, Francis A, O'Connor K, Ray L, Satin A, Guerra F, Hermann C, Kayne E, Sevi S, Braga R.] (Letter)
- 808a. Obituary: Alfred M. Freedman. *Psychiatric Times*, June 2011, pg 24.
- 808b. Obituary: Alfred M. Freedman. *Neuropsychopharmacology* 2011, 36:2784.
809. Book Review: Nash Boutros, Silvana Galderisi, Oliver Pogarell, Silvana Riggio: *Standard Electroencephalography in Clinical Psychiatry: A practical handbook*. Chichester UK: Wiley-Blackwell, 2011. *Acta psychiatr scand* 2011; 124: 239-40.
810. Book Review. *Will I Ever Be the Same Again? Transforming the Face of ECT (Shock Therapy)*. *J ECT* 2011; 27:262-3 [Kellner CH, Fink M.]
811. Book Review. Hobson, J.Allan. *Dream Life: An Experimental Memoir*. *Science Books & Films* 2011; 47(4):186.

2012

812. Hidden in plain sight: Catatonia in pediatrics. *Acta psychiatr scand*. 2012: 125:11-12. [Commentary]
813. *Oral History of Neuropsychopharmacology: The First Fifty Years: Neurophysiology*. Thomas Ban and Max Fink, Editors. Brentwood TN: ACNP. Volume 2: 319 pp.
814. Book Review: Bor, Daniel *The Ravenous Brain: How the New Science of Consciousness Explains our Insatiable Search for Meaning*. *Science Books & Films* 2012; 48(9): 243-4.
815. The responsible role for ECT in suicide prevention and treatment. In: A. Shrivastava, M. Kimball, D. Lester (Editors): *Suicide from a Global Perspective: Risk Assessment and Management*. Chap 14: pg 119-126.

2013

816. Rediscovering Catatonia: The Biography of a Treatable Syndrome. *Acta psychiatr Scand*. 2013; 127: Supplement 441;1-50. [Fink M.]
817. Clinical practice to change with divorce of catatonia and schizophrenia. *J Clin Psychopharmacology* 2013; 33(3): 287-88. [Fink M.]

818. Electroconvulsive therapy (ECT) for children, adolescents and adults with developmental disability and severe mental illness: A call for action. *Am J Psychiatry* 2013 [Wachtel L, Dhossche D, Fink M, Jaffe R, Kellner CH, Weeks H, Shorter E.] (Editorial).

819. Are depression's causes biological? *The New York Times*, September 16, 2013; pg A22. Letter. [with Edward Shorter].

820. Introduction. *Electroconvulsive Therapy: A Guide for Professionals and their Patients*. Korean Edition; translated by Sangsoo Lee. Seoul S. Korea: Hana Medical Publishing Co., 233 pp. [Fink M.]

821. The Diagnostic and Statistical Manual of Mental Disorders, Fifth edition, divorces catatonia from schizophrenia. *J Clin Psychopharmacology*. 2013; 33(3):1-2.

2014

822. The mechanism of action of ECT. In: N. Ghaziuddin and G. Walter (Eds.): *Electroconvulsive Therapy in Children and Adolescents* 2014. New York: Oxford University Press. Chap 2, pp 18-28. [Fink M.]

823. The role of ECT in suicide prevention. *J ECT*:30: 5-9. [Fink M, Kellner CH, McCall V.]

824. What was learned: Studies by the Consortium for Research in ECT (CORE) 1997-2011. *Acta Psychiatrica Scand*. 129: 417-426. [Fink M.]

825. Thirty years of publication and continuing. [Editorial] *J ECT* 30: 1-2 [McCall WV, Kellner CH, Fink M.]

826. Celebrating 80 years of inducing brain seizures as psychiatric treatment. *J ECT* 2014; 30:90. [Fink M.]

827. Revive flurothyl inhalation treatment in psychiatry? *Psychiatric Times* March 19, 2014 [Fink M, Shorter E]

828. The seizure, not electricity, is essential in convulsive therapy: The flurothyl experience. *J ECT* 2014; 30:91-93. [Fink M.]

829. The chemical induction of seizures in psychiatric therapy: Were flurothyl (Indoklon) and pentylenetetrazol (Metrazol) abandoned prematurely? *J Clinical Psychopharmacology*. 2014; 34(5):602-7. [Cooper K, Fink M.]

830. Convulsive and non-convulsive treatments in psychiatry. In: S. Bloch, S. Green, J Holmes (Eds.): *Psychiatry: Past, Present and Prospect*. New York: Oxford University Press, 2014.

831. Obituary. Turan M. Itil. *Neuropsychopharmacology* 2014; 39:3133-3134

2015

832. Electroconvulsive therapy versus pharmacotherapy for bipolar depression. *Am J Psychiatry* 2015; 172(3) 295-6. [Kellner CH, Fink M.]

833. Reply. [Comment on Wachtel L: Recognition of neuroleptic malignant syndrome and delirious mania as malignant catatonia in an autistic man with prompt relief with ECT.] *Acta Psychiatr Scand*. 132:320

834. Seeing the King's frenzy as catatonia. *Acta psychiatr scand* 132(6): 500-501.

835. Book Review. Le Bihan, Denis. *Looking Inside the Brain: The Power of Neuroimaging*. Princeton U Press. AAAS Science Books & Films.

2016

836. Catatonia is a systemic medical disorder. *Acta psychiatr scand*. 2016; 133(1): 250-1. [Fink M, Fricchione G, Rummans T, Shorter E.]

837. Bearing Witness: Personal and poetic descriptions of seizure therapy. *J ECT* 2016; 32(1): 13-16. [Fink M.]

838. Optimizing ECT technique in treating catatonia. *J ECT* 2016; 32(3):149-150. [Fink M, Kellner CH, McCall V.]

839. Barbara Fish: In Memoriam. *Neuropsychopharmacology* 2016; 41(13): 3118.

840. Hyperthermia for Major Depressive Disorder? *JAMA Psychiatry*. 2016 Oct 1; 73(10): 1096. 2016.1627. [Fink M, Shorter E.]

2017

841. Katatonie: Často Sevyskytující Klinický Syndrom Rozpoznatelný a Léčitelný. Catatonia: A Common Systemic Clinical Syndrome, Recognizable and Treatable. *Čes a slov Psychiat* 2017; 113(2): 84–93.

842. Does persisting fear sustain catatonia? *Acta Psychiatr Scand* 2017; Nov; 136(5):441-444. [Fink M, Shorter E.]

843. To define melancholia, follow the path of catatonia. *Bipolar Dis* 2017;19(5);401- 2.

844. Electroconvulsive therapy for self-injurious behavior in autism spectrum disorders: Recognizing catatonia is key. *Current Opinion*. 2017 Dec 18 [Epub ahead of print]. [Wachtel LW, Shorter E, Fink M]

845. Book Review. Electroshock as Means for Social Control. Sadowsky, J. *Electroconvulsive Therapy in America: The Anatomy of a Medical Controversy*. *JECT* 2017; 33:144-5.

846. ECT for catatonia and melancholia: No need for ambivalence. *Psychiatric Times* 2017; Sep: 16-17F. (Kellner CH, Fink M).

2018

847. ECT for Self Injurious Behavior in Autism: A New Indication. *Psychiatric Times*. 56 (2): 6-9. [Wachtel LE, Kellner CH, Fink M.]

848. Book Review: Electroconvulsive Therapy: Revival in German speaking Countries. *JECT* 34:70-71.

849. *The Madness of Fear: A History of Catatonia*. NY: Oxford University Press. [E. Shorter, M. Fink]

850. Electroconvulsive therapy for self-injurious behavior in autism spectrum disorders: Recognizing catatonia is key. *Current Opinion*. 2018; 31(2):116-122 [Wachtel LW, Shorter E, Fink M]

851. Induced seizure therapy (ECT): Effective and safe, but stigmatized. *Scientific American Psychiatry*. DOI 10.2310/7800.13068 08/17

852. A useful example of pharmaco-electroencephalogram science. *J Clin Psychopharmacology* 38(6): 552-554. (Invited Commentary).

2019

853. Electroshock Therapy and Catatonia: A Productive Synergism. *JECT* 2019; 35(4):219-221.

854. Catatonia: A Recognizable and Treatable Systemic Syndrome. In: *Oxford Textbook of Neuropsychiatry*, Chap 36; 437-445. NY: Oxford University Press, 2019

855. Book review: Semple, David. Pragmatic Guidance for EEG Interpretation. 2nd edition. Amazon Digital Services LLC, *JECT* 35(4):e60-61.2020

2020

856. Expanding the catatonia tent: Recognizing electroconvulsive therapy responsive syndromes. *JECT*: 2020 Oct 27. doi: 10.1097/YCT.0000000000000729

857. A protocol for a prospective descriptive prevalence study of catatonia in an acute mental health unit in urban South Africa. *BMJ Open*. Zingela, Z, Cronje J, Fink M, Van Wyk, S. *BMJ Open* 2020;**10**:e040176. doi: 10.1136/bmjopen-2020-040176

2021

858. Random Controlled Trial of Sham ECT Therapy: A Historical Note. *JECT* 2021 Mar 4. doi: 10.1097/YCT.0000000000000759. Online ahead of print. PMID: 33661180

Internet, Web-Based Articles

1998

W.01 Is catatonia a subtype of schizophrenia?

<http://www.mhsource.com/whatsnew/mfin-catatton.html>

W.02 EEG monitoring in ECT: A guide to treatment efficacy.

<http://www.mhsource.com/pt/p980570.html> with Richard Abrams

1999

W.03 Pediatric ECT: An update.

<http://www.mhsource.com/pt/p990963.html> with Carmel Foley

W.04 Electroshock. An effective treatment for mental illness.

<http://www.electroshock.org>

W.05a The use of ECT in bipolar disorder (Consumer)

<http://www.mhsource.com/bipolar/ect2.html>

W.05b The use of ECT in bipolar disorder (Professional)

<http://www.mhsource.com/bipolar/ect1.html>

2000

W.06 Pediatric ECT . A Review, June 2000.

http://www.electroshock.org/archives/adolescent_ECT_review.htm

W.07 NMS is best treated as catatonia.

http://www.electroshock.org/archives/NMS-catatonia_review.htm

W.08 ECT 2000.

<http://www.longislandpsych.org/arch/ECT/ECTframe.html>

W.09 ECT 2000.

http://www.mdvista.com/library/journal/psychiatry/electroconvulsive_therapy_2000.htm

2001

W.10 ECT is effective in bipolar disorder.

<http://www.BMJ.com/cgi/content/full/321/7272/1302>

W.11 Treating bipolar affective disorder.

<http://www.bmj.com/cgi/content/full/322/7282/365/a>

W.12 Neuroleptic malignant syndrome and malignant catatonia: Effective treatment,

<http://www.mdvista.com/>

2002

W.13 Insulin coma therapy.

http://www.pbs.org/wgbh/amex/nash/filmmore/ps_ict.html

2005

W.14 The social sources of psychopharmacology.

<http://media.snow.utoronto.ca:8080/ramgen/extra4/BE2005/BE2005-April29-5.rm>

2009

W.15 ECT in treating status epilepticus.

<http://dx.doi.org/10.1016/j.yebeh.2009.06.022>

2011

W.16 The race to Patent bio-Tests for Schizophrenia and Depression.

<http://www.psychiatrictimes.com/schizophrenia/content/article/10168/1994367>

Updated April 15, 2019